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ABSTRACT 
In recent years, there was a big market growth in the pharmaceutical industry (World Health 
Organization, 2011).  As a result, there has also been an increase in pharmaceutical pollutants 
present in the environment (Weber et al, 2014). These emerging pharmaceutical pollutants are 
common human pharmaceutical compounds (HPCs) such as ibuprofen (IBU), paracetamol 
(PAR), acetylsalicylic acid (ASA), and amoxicillin (AMOX). When consumed, the 
unmetabolized drugs and their metabolites reach the environment through human excretion. 
Because they are biologically active, a small amount can be a source of possible problems for 
aquatic creatures (Bacsi et al, 2016). Because some pharmaceutical components are very 
recalcitrant to common wastewater treatment techniques, new wastewater treatment processes 
are being explored (Ghafoori et al, 2014). A new composite adsorbent material is created in 
order to address the separation difficulty and the limited adsorption of other adsorbents. The 
aim of this research is to synthesize a magnetic activated carbon  adsorbent (PACMAG) that 
combines the adsorbing capabilities of powdered activated carbon (PAC) and the magnetic 
properties of iron oxide nanoparticles (FeNPs).  
The FeNPs, were synthesized by co-precipitation in a basic medium which resulted in a 
quantitative yield, the afforded particles have a positive zeta potential and a point of zero charge 
between pH 8 and 9. These were then embedded in powdered activated carbon in order to 
produce PACMAG with 103 ± 5 % yield. PACMAG was first tested for its adsorption capacity 
in various HPCs, namely IBU, PAR, and ASA. The adsorption ability of PACMAG was 
assessed from isotherms of 24 hours. The adsorption of IBU by PACMAG, which was the 
chosen model compound for aromatic analgesics was further optimized. Several adsorption 
isotherms were determined by varying the amount of adsorbent and drug present in the system. 
The behavior of IBU was compared with AMOX, a non-aromatic antibiotic. Based on the 
behavior of both HPCs (IBU and AMOX) in the presence of PACMAG, the optimum 
parameters for the adsorption are 120 min adsorption time for 15 mg/L drug concentration, and 
300 mg/L PAC content in the adsorbent. This resulted in a 92.22 ± 0.08 % and in a 79.90 ± 
0.05 % removal for IBU and AMOX respectively. In the same conditions, IBU and AMOX 
adsorption was tested using the wastewater (WW) from Estação de Tratamento de Águas 
Residuais (ETAR) as solvent. In wastewater, a decreases in drug adsorption to 49.52 ± 0.15 % 
and 26.54 ± 0.01% IBU and AMOX, respectively, was observed. This is due to the presence 
of other organic molecules in the system that compete for the adsorption sites. By increasing 
the PAC content of the adsorbent to 1000 mg/L, which was done for AMOX, the percent 
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removal can be increased up to 76.720 ± 0.001 %. Finally, PACMAG can be regenerated using 
the Fenton reaction. The regenerated PACMAG removed 53.840 ± 0.004% of AMOX in an 
AMOX-WW mixture. Based on the sedimentation test, PAGMAG is more time efficient 
because it requires 5 minutes at the presence of a magnet to settle, and separate the particles 
from the water supply.  
The results of this work can contribute for the improvement of water treatment processes 
particularly in the removing of HPCs. Being nowadays, this kind of compounds is a growing 
problem in water treatment. 
 
Keywords: Magnetic Activated Carbon, Magnetite Nanoparticle, Activated Carbon, Water 
Treatment Analysis, Human Pharmaceutical Compounds, Adsorption 
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RESUMO 
Nas últimas décadas assistiu-se a um enorme crescimento da Industria Farmacêutica (World 
Health Organization, 2011), o que levou a um aumento exponencial da quantidade e do número 
de compostos de origem farmacêutica que se podem encontrar no ambiente (Weber et al, 2014). 
Este novo tipo de poluentes designados por “human pharmaceutical compounds” (HPCs), 
como o ibuprofen (IBU), o paracetamol (PAR), o ácido acetilsalicílico (ASA), ou a amoxicilina 
(AMOX). 
Quando consumidos, tanto as drogas não metabolizadas como os seus metabolitos são 
libertados no ambiente por via das excreções. Sendo as drogas, e, ou os seus metabolitos 
biologicamente ativos, mesmo uma pequena quantidade dos mesmos pode ter impacto sobre 
os seres presentes nos meios aquáticos (Bacsi et al, 2016). Sendo alguns destes compostos 
particularmente resistentes aos tratamentos comummente usados no processamento das águas 
residuais, tal tem levado à procura de novos processos de tratamento de águas residuais 
(Ghafoori et al, 2014). 
Neste trabalho mostramos os resultados obtidos com um novo material compósito criado de 
modo a maximizar a adsorção e a facilitar o processo de separação e regeneração do adsorvente. 
Assim damos conta da síntese do um adsorvente de carvão ativado com propriedades 
magnéticas (PACMAG), este material combina a capacidade de adsorção do carvão ativado 
pulverizado (PAC) e as propriedades magnéticas de nanopartículas de óxido de ferro (FeNPs). 
As nanopartículas de óxido de ferro (FeNPs) foram sintetizadas por coprecipitação em meio 
básico, por este método foi possível obter nanopartículas com um rendimento quantitativo, 
mostrando estas um potencial zeta positivo, e uma ponto de carga zero a pH entre 8 e 9. Estas 
partículas forma posteriormente embutidas em carvão ativado pulverizado, resultando o novo 
material PACMAG.  
Foi testada a capacidade de adsorção de diversos HPC, nomeadamente o IBU, o PAR e o ASA, 
pelo PACMAG. Foram realizadas isotérmicas ao longo de 24 horas. O IBU foi escolhido como 
composto modelo para os analgésicos aromáticos, tendo sido as condições otimizadas para este 
composto. O comportamento do IBU foi comparado com o da AMOX, um antibiótico não 
aromático. De acordo com os resultados obtidos para estes dois fármacos foi determinado que, 
para concentrações de 15 mg/L de droga, o tempo de contacto necessário é de 120 minutos, e 
que o conteúdo em PAC ótimo, do adsorvente, é de 300 mg/L. Nestas condições observou-se 
uma remoção de 92,22 ± 0,08 % e de 79,90 ± 0,05 % para o IBU e a AMOX respetivamente. 
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Em condições idênticas, foram repetidos, os testes de adsorção do IBU e da AMOX, usando 
água residual (WW) de uma Estação de Tratamento de Águas Residuais (ETAR) como 
solvente. Nestas condições observou-se uma diminuição da quantidade de droga adsorvida para 
49,52 ± 0,15 % e 26,54 ± 0,01% para o IBU e para a AMOX, respetivamente. Tal deve-se à 
presença de outras moléculas orgânicas que competem com os fármacos em estudo pelos sítios 
de adsorção. Aumentando a quantidade de PAC no adsorvente para 1000 mg/L, o que foi feito 
para o caso da AMOX, a remoção aumenta para 76,720 ± 0,001%. 
Finalmente mostra-se que o PACMAG pode ser regenerado usando a reação de Fenton. O 
PACMAG regenerado removeu 53,840 ± 0,004% de AMOX de uma solução AMOX-WW. De 
acordo com os testes de sedimentação o PACMAG necessita de apenas 5 minutos para na 
presença de um campo magnético sedimentar, de modo a permitir a sua separação da água 
tratada. 
Os resultados deste trabalho são uma contribuição para a melhoria dos processos de tratamento 
de águas residuais, em particular na remoção de HPC compostos cada vez mais prevalentes nas 
águas a tratar. 
 
 
Palavras Chave: Carvão Ativado com Propriedade Magnéticas, Nanopartículas de Magnetite, 
Carvão Ativado, Tratamento de Águas, Human Pharmaceutical Compounds, Adsorção 
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1 
 
OBJECTIVES OF THE RESEARCH 
 
For the past 2 years, there was a US$150 billion increase in global pharmaceutical demand due 
to increasing global public consumption (World Health Organization, 2011).  Once consumed 
these unmetabolized drugs and their metabolites are normally excreted in urine and feces which 
end up in wastewater treatment plants (WWTPs). Wastewater treatment plants can remove 
some of these pharmaceutical contaminants, but not all are removed. Some pharmaceutical 
components are very recalcitrant or persistent and the usual wastewater treatment processes are 
inefficient in their removal (Ghafoori et al, 2014). As a result, these contaminants are 
discharged in water bodies and present in sludges, contaminating the environment. Even 
though their concentration is low, these drugs and their metabolites are bioactive which can 
affect aquatic species. 
 
In order to address this problem, a new wastewater treatment process must be optimized or 
developed. Adsorption through activated carbon is promising in the removal of these 
contaminants from wastewater (WW). Powdered activated carbon (PAC) is an excellent 
adsorbent, but it requires an additional filtration step in order to separate it from the effluent 
(Borghi and Fabbri, 2013). On the other hand, studies had shown that iron oxide nanoparticles 
(FeNPs) have big surface area, due to its small size, and can be magnetically separated 
(Stefusova et al, 2012). However, these nanoparticles have a natural tendency to aggregate in 
aqueous solutions, decreasing their adsorption capacity (Atta et al, 2015). Thus, work must be 
done in trying to maximize the adsorption capacity of the PAC, and the magnetic property of 
FeNPs to increase PAC and pharmaceutical removal.  
 
The aim of this research is to develop a composite magnetic activated carbon adsorbent 
(PACMAG) which can remove pharmaceuticals (like e.g. IBU, PAR, ASA, and AMOX) from 
wastewater (WW). 
  
The main objective of this study was obtained by achieving the following steps: 
 Synthesis and characterization of the FeNPs based on particle size and zeta potential in 
varying pH and ion concentrations 
 Synthesis of PACMAG using the FeNPs and PAC  
2 
 
 Analyze FeNPs and PACMAG kinetics in various aqueous drug solutions (IBU, PAR, 
ASA, and AMOX) 
 Determine PACMAG isotherms in various aqueous drug solutions (IBU and AMOX),  
 Compare the sedimentation of PACMAG using various sedimentation set-ups (with and 
without a magnetic force for 5 minutes, without a magnetic force for 30 min), 
 Determine the adsorption capacity of PACMAG to remove IBU or AMOX in WW, 
 Perform preliminary tests on the regeneration of PACMAG. 
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1 INTRODUCTION 
 
1.1 Pharmaceutical Contaminants in Water  
Currently the pharmaceutical industry is gaining advancement in the global market. Since 
2014, 90 new human pharmaceutical compounds (HPCs) have been approved by the Food and 
Drug Administration (FDA) (CEN RSS, 2016).  According to the World Health Organization 
(WHO), in just 2 years (2013-2015) the global pharmaceutical sales would increase by US$ 
150 billion, amounting to a total of US$ 900 billion (World Health Organization, 2011). There 
is a big demand for pharmaceuticals annually which is based on the global public consumption 
of medicines. Contrary to the increase in innovation, the pharmaceutical companies currently 
spend one-third of all sales revenue on marketing strategies and not on research and 
development. As a result, many of these new drugs move in the global market not due to their 
ability to transform lives, rather, to gain profit according to the Chemical Engineering News 
(C&EN) (CEN RSS, 2016) 
 
As an indirect effect of the high consumption of these HPCs, studies showed that they would 
eventually reach different environmental sinks (Shalini et al, 2010). According to the Strategic 
Approach to International Chemical Management (SAICM), there had been an emerging issue 
of pharmaceuticals in the environment resulting to the term environmental persistent 
pharmaceutical pollutants (EPPP) (SAICM, 2016). EPPP are defined as compounds that have 
not been studied before and are not currently covered by existing water-quality regulations. 
This includes the pharmaceutical residues and metabolites with potential of contaminating the 
environment (water, soil, organisms) (EUR-Lex, 2016). Table 1.1 depicts the number of EPPP 
found in aquatic environment in numerous countries. It also shows the variety of drugs that can 
be an EPPP namely analgesics, estrogens and antibiotics. Most of the EPPP are common drugs 
such as IBU, ASA, and PAR (Weber et al, 2014). Because of the amount of these HPCs that 
are being used by the public, they can eventually be problematic (Geissen et.al, 2015). 
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To give a more vivid scope of the prevalence of EPPP contamination in water, Figure 1.1 shows 
that the problem has been present all over the world. This problem is not just present in 
developing countries in Africa and Asia. They also affect countries in Europe and America 
(Weber et.al, 2014). According with Lapworth et al (2012), the pharmaceutical concentrations 
found in aquatic environment were considerably low to cause acute effects. But, it could bring 
major concerns in the future because of their high consumption and production. 
 
Table 1.1: Emerging contaminants detected in European ground waters and surface 
waters water treatment or other pint sources (Weber et.al, 2014) 
 
 
 
Figure 1.1: Global occurrence of pharmaceuticals that have been found in the 
environment in all UN regional groups (Weber et.al, 2014) 
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An example of HPCs contamination in the environment was observed in the northwest of 
France. According to Mompelat et al (2011), among the 20 HPCs that were being monitored, 
16 had been quantified in both surface and drinking water. Their concentration was found to 
be 22% above the limit of quantification for surface water, and 14 % for drinking water. The 
HPCs found in surface and drinking waters included psychostimulants, non-steroidal anti-
inflammatory drugs, iodinated contrast media, and anxiolytic drugs (Mompelat et al, 2011). 
Studies in the removal of HPCs and its metabolites from drinking water by activated carbon 
adsorption, oxidation by ozone, or disinfection by chlorine have been done. Some HPCs are 
resistant to these treatment. Also specific processes in removing HPCs are expensive, time 
consuming, and produces by-products of greater concern (Borghi and Fabbri, 2013).  
 
Often these recalcitrant pharmaceutical compounds were retained in both the effluent and solid 
sludge as either the unmetabolized parent drug and/or metabolites (Ghafoori et al, 2014). This 
was supported by Murdoch (2015) such that when the contaminated effluents were released or 
reused as irrigation or the sludge was used as fertilizer, they could contaminate plants and leak 
to possible source of drinking water. An example is carbamazepine, an anti-epileptic drug, 
which could not be removed by secondary wastewater treatment. This drug with its metabolites 
were detected in treated water and crops like pepper, collard, lettuce, radish and tomato 
(Murdoch, 2015). It was discovered that certain areas in Spain had its soil and water 
contaminated with carbamazepine, lamotrigine (anticonvulsant), sildenafil (active component 
of Viagra), sulfapyridine (antibiotic), and metoprolol (beta-blocker) due to the recycling of 
effluents and sludges for agricultural purposes (Rodriguez-Navas, 2013). 
 
EPPP are continuously entering into aquatic environment, directly or indirectly (Swedish 
Association of the Pharmaceutical Industry AB, 2004). There are 3 different routes at which 
these HPCs reach the environment. They can be introduced by improper disposal of unused 
HPCs, by leaks in the manufacturing process, and by human and animal wastes which reach 
the water supply through the sewage system or leaching in the soil (Swedish Association of the 
Pharmaceutical Industry AB, 2004).  
 
According to Stuart et al (2012), there were hospital facilities disposing their unused medical 
products improperly by throwing untreated drugs or flushing them with water. Also, 
agricultural usage such as veterinary medicines were sometimes thrown in the soil and these 
medicines leached through bodies of water. It was detected that in the early 1990’s there were 
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HPCs discharges in the environment by manufacturing plants (Larsson, 2014). But, little 
attention was given to it because of the limited analytical devices that could measure such 
reduce concentrations (Larsson, 2014). The problem was ignored only until evidences of the 
feminization of fish due to the presence of oestrogens from manufacturing plants were found 
(Larsson, 2014). Larsson et al (2007) recorded a high emission of HPCs from drug 
manufacturers in Patancheru, India. It was noted that the concentration of ciprofloxacin, a 
broad spectrum antibiotic, reached 31 mg/L, which was 1 million times more that the regular 
level found in other areas and was very toxic for organisms. At this concentration, the total 
release of these drug was 44 kg per day, which was sufficient to treat 44,000 inhabitants 
(Larsson, 2014). Aside from India, other Asian countries like Korea, Taiwan and China 
exhibited high concentrations of HPCs leakage from manufacturing companies (Cui et al, 
2006). In China, 51 ng/L of ethinyloestradiol was detected in a river, which affected the 
reproduction of aquatic vertebrates (Cui et al, 2006). There were reports in the USA and Europe 
of manufacturing companies releasing high concentrations (mg/L) of HPCs in the environment 
as well (Larsson, 2014). 
 
It is presented in Table 1.2 the different HPCs that were detected in the environment due to 
improper disposal and manufacturing leakage. Globally, large amounts of HPCs appeared in 
different environmental mediums in the past 16 years and most of them had high concentrations 
ranging in the milligrams per liter range. Drugs ranged from antibiotics, anti-inflammatories, 
analgesics, hormones, antivirals, and anti-depressants. 
 
Table 1.2: Studies on the industrial effluents (IE), river sediments (RS), soil, ground water 
(GW) and surface water (SW) where presence of HPCs are detected 
 
Country HPCs detected Drug type Matrices:  Drug 
Concentration 
Year Reference 
China oxytetracycline Antibiotic IE: 1065 mg/L 1988 Qiting and 
Xiheng, 
1988 
India Salicylic acid Anti-
inflammatory 
IE:  2270 mg/L 1993 Bisarya and 
Patil, 1993 
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Denmark Sulfonamide 
intermediates 
and metabolites 
Antibiotics,  GW: 
Sulfaguanidine 
(1.6 mg/L) 
1995 Holm et al, 
1995 
Germany Phenazone and 
metabolites 
Analgesic GW: Phenazone 
(3.95 μg/L) 
TW: Phenazone 
(0.4 μg/L) 
2002 Reddersen et 
al, 2002 
Germany Phenazone and 
metabolites 
Analgesic GW: Phenazone 
(2.5 μg/L) 
TW: Phenazone 
(0.25 μg/L) 
2004 Zühlke et al, 
2004 
Switzerland Venlafaxine Antidepressant SW: 0.8 μg/L 2004 Amt für 
Umwelt und 
Energie 
Basel-Stadt, 
2004 
Norway Bacitracin Antibiotic IE: 250 kg/ 
discharge 
2005 Norwegian 
Environment 
Agency, 
2005 
China Oestrogenic sex 
steroids 
Hormones IE: 
Ethinyloestradiol 
(51 ng/L) 
2006 Cui et al, 
2006 
India Various drugs 
including 
fluoroquinolone 
Various IE: Ciprofloxacin 
(31mg/L) 
2007 Larsson et 
al, 2007 
China Oxytetracycline Antibiotic IE: 19.5 mg/L 
SW: 712 μg/L 
2008 Li et al, 2008 
Taiwan Various drugs Various SW: Diclofenac 
(27 μg/L) 
2008 Lin et al, 
2008 
Croatia Sulfonamide Antibiotic IE: Sulfaguanidine 
(>1.1 mg/L) 
2008 Babic et al, 
2007 
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China Penicillin and 
metabolites 
Antibiotic IE: Penilloic acid 
(44 mg/L) 
SW: Penilloic acid 
(11.6 mg/L) 
2008 Li et al, 2008 
Taiwan Various drugs Various IE: 
Sulfametoxazle 
(1.34 mg/L) 
Ibuprofen (1.5 
mg/L)  
2009 Lin and Tsai, 
2009 
India Various drugs 
including 
fluoroquinolone 
Various IE: Ciprofloxacin 
(14mg/L) 
GW: Cetirizine (28 
μg/L) 
SW: Ciprofloxacin 
(6.5 mg/L) 
2009 Fick et al, 
2009 
Switzerland Oseltamivir Antiviral SW: 160 ng/L 2010 Prasse et al, 
2010 
USA Metaxalone Relaxant IE: 3.8 mg/L 2010 Phillips et al, 
2010 
India Fluoroquinolone Antibiotic RS: Ciprofloxacin 
(914 mg/kg of 
organic material) 
2011 Kristiansson 
et al, 2011 
Korea Lincomycin Antibiotic IE: 43.9 mg/L 2011 Sim et al, 
2011 
Israel Venlafaxine and 
metabolites 
Antidepressant IE: Venlafaxine 
(11.2 μg/L) 
2012 Gasser et al, 
2012 
Israel Carbamazepine 
and venlafaxine 
Various IE: Venlafaxine 
(11.7 μ/L) 
2013 Lester et al, 
2013 
Pakistan Various 
antibiotics 
Antibiotic SW: 
Sulfamethoxazole 
(49 μg/L) 
2013 Khan et al, 
2013 
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India Fluoroquinolone Antibiotic GW: 
Ciprofloxacin (770 
ng/L) 
Soil: 
Ciprofloxacin (7.2 
μg/g of organic 
matter) 
2014 Rutgersson 
et al, 2014 
Spain Venlafaxine Antidepressant IE: 2.6 μg/L 2014 Collado et 
al, 2014 
 
Aside from the improper disposal and manufacturing leakage, a more common source of 
contamination is through human and animal excreted products. HPCs are bioactive compounds 
primarily designed and prescribed to have specific biological effects on the human body. 
Depending on their metabolization, HPCs can be excreted from the human body as 
unmetabolized parent compounds and/or metabolites in urine and/or feces (Mompelat et al, 
2011). These body wastes containing the unmetabolized drug and its metabolites are discharged 
in houses and enter in WWTP. Some examples of the HPCs found are ibuprofen, gemfibrozil, 
paracetamol, triclosan, aspirin, naproxen, ampicillin, amoxicillin, nicotine, oesterone bisphenol 
A (Stuart et al, 2012). These HPCs usually range from a concentration of 10 to 1000 ng/L 
(Lapworth et al, 2012). 
 
Gavrilescu et al (2015) observed that the occurrence and concentrations of HPCs in water 
varied with the local of sampling, the time at which they were obtained, and the efficiency of 
the treatment plant in removing these contaminants. In general, the concentration of HPCs in 
water during summer was higher compared to its concentration during winter because 
precipitation was more frequent in winter causing a natural dilution (Nam et al, 2014). While 
in terms of location, the frequency and probability at which HPCs could be detected was higher 
at sources near urban areas than in agricultural or undeveloped areas. But, this did not mean 
that the HPCs concentration was greater because other factors such as natural attenuation, 
chemical and physical property of the HPCs could also affect it (Fram and Belitz, 2011). 
 
Trembley et al (2011) referred that there were 156 new EPPPs that could cause environmental 
concerns. These new EPPPS included analgesics, antibiotics (AMOX) and antibacterial drugs 
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(ciprofloxacin, erythromycin, tetracycline, sulfamethoxazole), contrast media (lopromide, 
iopamidol), prescription drugs (benzodiazepines, salbutamol, carbamazepine), and generic 
medicines (IBU, PAR, ASA). Aside from this, steroids and hormones namely androgens 
(testosterone, androstenedione), estrogens (estrone, estriol, estradiol), xenoestrogens 
(ethynilestradiol, diethylstilbestrol), and anti-inflammatory drugs could cause great concern as 
well (Tremblay et al, 2011). Table 1.3 shows the 4 HPCs studied in this research are among 
the top 20 most commonly used. As a result, they have a high probability to be present in most 
water systems  
 
 
These 4 HPCs were also the most produced and consumed medicines in Germany, a leading 
country in the chemical industry (Figure 1.2) (Küster and Adler, 2014).  
Table 1.3: Top 20 used EPPPs which appear in influents and effluents of 
typical New Zealand wastewater of urban origin (Tremblay et al, 2011) 
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1.2 Common Human Pharmaceutical Compounds  
According to the WHO model list of essential medicines (World Health Organization, 2013), 
these drugs are considered the most important medications needed in a basic health system, 
which makes them very available. In addition, IBU, PAR and ASA can be purchased as a 
generic medicine without the need of a prescription (World Health Organization, 2013) 
 
1.2.1 Ibuprofen  
Ibuprofen (IBU) (Figure 1.3) is a non-prescription medicine, nonsteroidal, anti-inflammatory 
drug which is used primarily to treat minor pain, fever, and inflammation (Rainsford, 2009).  
 
 
 
Figure 1.2: Most selling environmentally relevant HPCs in Germany in 2012 and 
HPCs with an annual consumption of more than 80 tons (Küster and Adler, 2014). 
 
Figure 1.3: Chemical structure of Ibuprofen  
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It works by inhibiting the synthesis of prostaglandin which is the reason of inflammation 
(Rainsford, 2009). It was derived from propionic acid by a team led by Stewart Adams in 1961 
as a safer alternative to aspirin. It was later on patented in the same year (Halford et al, 2012). 
 
Between 2002 and 2012, the consumption of IBU in Germany increased from 250 t up to 975 
t (Küster and Adler, 2014). Currently, globally, roughly 16, 500 t of IBU are produced and 
consumed by the public (FDA, 2015). Because of this, it has often been found in water ways 
excreted by humans because of incomplete metabolization. Rainsford (2009) referred that 77 
% up to 85 % of ingested ibuprofen were excreted in the form of urine by the body. Based on 
the study of Bacsi et al (2016), when these body wastes reached the environment, IBU in the 
wastes could promote growth of unicellular cynobacteria because the organism was not greatly 
affected by the changes in the chlorophyll-a content which the drug normally attacked. The 
number of functional groups in the cyanobacteria samples composed of Synechococcus 
elongates, Microcystis aeruginosa, and Cylindrospermopsis raciborskii, did not change 
drastically unlike in eukaryotic algae. On the other hand, the presence of IBU affected the 
chlorophyll-a content of natural eukaryotic algae such as the Cryptomonas ovata, flagellated 
green alga Haematococcus pluvialis, and the non-motile green alga Desmodesmus communis, 
thus, limiting its growth (Bacsi et al, 2016). Also, IBU contamination also inhibited the growth 
of aquatic plants (Boxall, 2004).  
 
Several environmental studies conducted all over the world resulted in the presence of 
ibuprofen at varying concentrations.  In the United States roughly 139 streams contain IBU, 
9.5 % of these streams contained an IBU concentration between 0.018 μg/L and 2.11 μg/L 
(Kolpin et al, 2002). Also, 1.35 μg/L of IBU penetrated the drinking water system of the 
country (Kolpin et al, 2002). It was estimated that after 5 years, the concentration of IBU in 
these streams would increase by 1.0 μg/L (Kolpin et al, 2002). In Germany, the sewage 
effluents had an average IBU concentration of 0.22 μg/L(Küster and Adler, 2014). In general, 
IBU has a detection frequency of above 50% which makes it more probable than any other 
HPCs in the market (Küster and Adler, 2014). 
 
1.2.2 Acetylsalicylic Acid  
Acetylsalicylic acid (ASA) (Figure 1.4) also known as aspirin is a white, acidic, odorless solid 
used to address some illnesses such as fever, inflammation and body pains or cramps. It is a 
stable molecule and is non-reactive in dry air (Schriks et al, 2010). But, it can hydrolyze in 
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moist air and dissolve in water (Schriks et al, 2010). It is considered as a nonsteroidal anti-
inflammatory drug. But unlike most drugs of its kind, the salicylates of aspirin affect the 
enzyme in an irreversible manner (Burke et al, 2006). It was discovered in 1853 by Charles 
Frederic Gerhardt wherein he was able to prepare the first ASA (Mahdi et al, 2006). But before 
it was synthetically made, the active ingredient of ASA namely salicylic acid was already being 
obtained from the extracts of the willow bark and spiraea plants which Hippocrates used to 
alleviate pains and fevers (Mahdi et al, 2006). Because “Aspirin” was being used for many 
years by manufacturing chemists, Bayer lost its trademark in 1918 (Cheng, 2007).Today, 
aspirin is a generic word in several countries. But Aspirin with a capital “A” remains to be a 
registered trademark of Bayer in over 80 countries (Cheng, 2007).  
 
 
Because ASA is one of the most common drugs used, the mass production of it can cause 
environmental issues. On average, more than 50,000 tons or 100 billion tablets of ASA are 
manufactured each year which leads to a high energy consumption and waste production 
(Schriks et al, 2010). According to Schriks et al (2010), ASA could be biodegraded at specific 
concentrations, and could be toxic to some organisms such as fishes and their embryos 
(Leuciscus idus > 100 mg/L) and daphnia (168 mg/L). Though these concentrations are high 
with regard to pharmaceutical contamination, it can still occur because ASA is widely 
consumed all over the world.   
 
1.2.3 Paracetamol  
Paracetamol (PAR) is also known as acetaminophen (Figure 1.5). It is a non-opioid analgesic 
and antipyretic which is often used for a large variety of mild to moderate illnesses (Silverman 
et al, 1992). Aside from a tablet form which can be taken orally, it has rectal formulation and 
intravenous formulation as well (Silverman et al, 1992). It was discovered in 1877 by Harmon 
 
Figure 1.4: Chemical structure 
of Acetylsalicylic Acid 
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Northrop Morse via the reduction of p-nitrophenol with tin in glacial acetic acid (Silverman et 
al, 1992). But it was only in 1887, 10 years after it was discovered, that it was administered to 
actual patients by Joseph von Mering who was a clinical pharmacologist (Bertolini et al, 2006). 
It is a non-prescription drug which comes in different forms. Due to its popularity, patents on 
PAR have long been expired and generic version of the drug is widely available (Thakkar and 
Billa, 2013).   
 
 
 
Because it is often used, PAR and its metabolites (paracetamol glucuronide and p-
aminophenol) are also present in the environment when secreted by the body. Its presence was 
confirmed in rivers having a concentration between 1.63 μg/L and 3.67 μg/L (Nam et al, 2014). 
It could be biodegraded and be used as a carbon source for Pseudomonas aeruginosa strain 
HJ1012 (Hug et al, 2014). The strain metabolized the drug into p-aminophenol. Aside from 
this, PAR could efficiently adsorbed onto sediments which would be further degraded by other 
microbial organisms. Even though there are many ways in degrading PAR, it is still recognized 
as a pseudo-persistent contaminant because of the amount of people using the drug worldwide. 
In 2009, roughly 3.2 billion tablets each year were consumed by each country in the western 
world (Bartelt-Hunt et al, 2009). Currently, the annual production and consumption of PAR is 
approximately 25 billion tablets (Dal Pan, 2015). It is pseudo-persistent because the probability 
of PAR being present in the environment versus to the rate it can be removed by 
physicochemical or microbial processes is higher (Kummerer, 2009). Thus, it has a continuous 
environmental presence but little information about its environmental behavior is known 
(Küster and Adler, 2014). Though PAR is non-toxic, has a low environmental effect, and non-
bio accumulating, it is still considered to be an EPPP because of its high prevalence in most 
environmental mediums (Küster and Adler, 2014).   
 
 
Figure 1.5: Chemical structure of 
Paracetamol  
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1.2.4 Amoxicillin 
Amoxicillin (AMOX) (Figure 1.6) is a β-lactam based antibiotic and is one of the many popular 
antibiotics that is used by both humans and animals (Yasser and Nabila, 2015). On the average, 
the annual consumption and production of AMOX is roughly 60,000 t (Yasser and Nabila, 
2015).  As a result, it has a high potential to reach the environment (Kaur et al, 2011). It is a 
solid substance that is very stable under normal conditions. Amoxicillin was discovered in 
1960s as one of the semisynthetic derivatives of 6-aminopenicilanic acid developed in 
Beecham, England (Ravina, 2014). It entered the market in 1972 after ampicillin (Ravina, 
2014). The patent for amoxicillin expired. Currently, its preparations are marketed under many 
trade names and have several synonyms across the world (Ravina, 2014). AMOX was one of 
the common antibiotics used with roughly 80 tons of purchases in Germany during 2012 
(Küster and Adler, 2014). 
 
 
 
According to Kaur et al (2011), unlike other drug contamination which were caused by human 
secretions, antibiotic contamination was mainly caused by animal husbandry industries. When 
animals were ill, they were treated with antibiotics whenever necessary. Typical to a normal 
organism, not all of the compound could be metabolized by the body. Thus they would be 
released in the environment through animal waste (Kaur et al, 2011).  These animal wastes 
were mixed with soil and used as soil fertilizers for crops, composting, and vermiculture 
(Moradi, 2015). As a result, these antibiotics leach through the soil and reach bodies of water.  
 
Because it is an antimicrobial drug, amoxicillin has a high toxicity hazard when it comes to 
aquatic organisms (Yasser and Nabila, 2015). Organisms constantly exposed to this drug can 
eventually produce immunity and resistance. Based on the overall risk assessment of 
amoxicillin, 60% of the parent compound is not metabolized by the body (Boxall, 2012).  
  
 
Figure 1.6: Chemical structure of Amoxicillin  
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1.3 Wastewater Treatment Plants  
In order to address the increasing concern on pharmaceutical contamination particularly the 
common HPCs such as IBU, PAR, ASA and AMOX, several wastewater treatment processes 
can be used before WW is released into the environment. Wastewater treatment plants 
(WWTPs) uses techniques to eliminate potential pathogens and solid impurities (undissolved 
substances, easily degradable organic substances, persistent organic substances, plant nutrients, 
heavy metals, and salts), and restore as much as possible the natural quality of water before it 
is released in the environment (Murdoch, 2015) (Donau Carbon GmbH, 2014).  
 
1.3.1 Common Decontaminating Techniques 
WWTPs follow increasing levels of WW treatment. Preliminary treatment has the objective of 
the removal of coarse solids and other large materials often found in raw wastewater (AWWA, 
2000). Removal of these materials is necessary to enhance the operation and maintenance of 
subsequent treatment units. Primary treatment involves the removal of organic and inorganic 
solids by sedimentation, and the removal of materials that will float (scum) by skimming 
(AWWA, 2000). Secondary treatment is the further treatment of the effluent coming from 
primary treatment. Its objective is to remove biodegradable dissolved and colloidal organic 
matter and suspended solids, using aerobic biological treatment processes (AWWA, 2000) 
Aerobic and anaerobic biological treatments are some of the treatments often used. In some 
WWTPs, tertiary and/or advanced wastewater treatment are employed when specific 
wastewater constituents which cannot be removed by secondary treatment must be removed 
(like nitrogen, phosphorus, additional suspended solids, refractory organics, heavy metals, 
dissolved solids, emerging contaminants) (World Health Organization, 2011). Because 
advanced treatment usually follows high-rate secondary treatment, it is sometimes referred to 
as tertiary treatment (Pescod, 1992). However, advanced treatment processes are sometimes 
combined with primary or secondary treatment (E.g., chemical addition to primary clarifiers or 
aeration basins to remove phosphorus) or used in place of secondary treatment (e.g., overland 
flow treatment or primary effluent) (Pescod, 1992), or used separately (E.G., chemical and or 
ultraviolet light techniques (Murdoch, 2015)). At the end of the treatment process, WWTPs 
produce a treated effluent and a treated sludge. The treated effluent is discharged into surface 
waters and reused as irrigation water. Sludges are disposed in landfills, incineration or used as 
soil fertilizers (Murdoch, 2015). Table 1.4 presents the common processes used in WW 
treatment. 
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1.3.2 Activated Carbon  
PAC is a non-graphite form of carbon, which is widely used in water/wastewater treatment 
(Tolga et al, 2014). PAC can be manufactured by carbonizing and activating various raw 
materials such as pine wood, coconut shell, coal, eucalyptus, peat, saw dust, rice husk and 
lignite (Rashed, 2013). In the carbonization process, most of the non-carbon elements like 
hydrogen and oxygen are first removed in the form of gas by heating the raw material at high 
temperatures (Tan and Hameed, 2010). The release of these elements is responsible in 
developing the internal pores of the PAC (Tan and Hameed, 2010). After which, the PAC is 
activated through chemical activation. In this process, it increases the number and dimension 
of the pores which increases the internal surface area (Enz et al, 2006). There are different types 
Table 1.4: Conventional and advanced wastewater treatment processes and their 
expected range of removal efficiency for pharmaceuticals  
(World Health Organization, 2011) 
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of pores present in PAC namely micro pore, meso pore and macro pore (Figure 1.7) (Enz et al, 
2006). The macro pores (25 nm <  pore radius) are where the contaminants can enter (Enz et 
al, 2006). The meso pores (1 nm < pore radius < 25 nm) act as the hallways or the corridors 
where the contaminants are transported (Enz et al, 2006). When the contaminants reach the 
micro pores (pore radius < 1nm), they start to adhere to the internal surfaces and adsorb within 
the PAC through intermolecular forces (Enz et al, 2006). The strength of the intermolecular 
forces in PAC are either weak or strong interactions (Sivasankar, 2008). A weak interaction 
(<40 kJ/mol) is the same as the interactions between molecules in liquids and allow for what 
is known as physical adsorption or physisorption (Sivasankar, 2008). Strong interactions (>40 
kJ/mol) are similar to the interaction between atoms within a molecule like covalent bonds and 
allow for chemical adsorption or chemisorption (Sivasankar, 2008). In chemisorption the 
molecule may be broken down and the fragmented molecule attaches on the surface of the 
adsorbent, this process is known as dissociative chemisorption (Sivasankar, 2008). Unlike in 
physisorption where the adsorbed molecule remains intact (Sivasankar, 2008). Because of the 
varying molecular size and interaction forces, adsorption is not constant. The smaller the 
molecular size of the contaminant, the deeper it can diffuse into the pores of PAC (Enz et al, 
2006). Thus, PAC can adsorb more contaminants with a smaller molecular size. At the same 
time,  the finer the PAC, the more accessible are its surface to contaminants leading to a faster 
the rate of adsorption (Sivasankar, 2008). The carbon adsorption process is controlled by the 
diameter of the pores in PAC and by the diffusion rate of organic molecules through the pores. 
The rate of adsorption is a function of the molecular weight and the molecular size of the 
organics (Upadhyayula et al, 2009).  
 
 
 
  
Figure 1.7: Pore structure and type of pores present in activated carbon 
(Begg Cousland, 2016) 
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Activated carbon can be used either in powdered (PAC) or granular (GAC) forms and is widely 
used to remove bio-resistant organic materials due to its simplicity in design, operation, 
regeneration, and cost (Ghafoori et al, 2014). PAC is used in combination with other treatment 
processes.  Due to its high efficiency, the activated carbon is usually used in the last treatment 
step to remove the most difficult impurities like pharmaceutical micropollutants (Donau 
Carbon GmbH, 2014). PAC adsorption in WWTPs is done by adding activated carbon, letting 
it mix with WW and allowing it to settle for a specific amount of time. In GAC adsorption WW 
passes through carbon packed columns or carbon filter bed. (Donau Carbon GmbH, 2014).  
 
Studies showed that activated carbon could remove organic substances and colorants, reduce 
the amount of trace substances like chemicals and pharmaceutical, and decrease the residual 
chemical oxygen demand in a WWTP (Donau Carbon GmbH, 2014). Based on the study of 
Ghafoori et al (2014), approximately 1.07 kg of carbon/L of pharmaceutical WW were required 
to remove 320 mg of carbon/L of effluent TOC, since the activated carbon followed the 
Langmuir isotherm which meant that only a monolayer, homogeneous adsorption could occur.    
 
1.4 Iron Nanoparticles  
Nanoparticles (NPs) can help in water treatment (Carlos et al, 2013). A common type of NP 
being used in different applications like water treatment and biological applications is nano-
iron oxide due to its size, abundancy, and magnetic property (Ambashta et al, 2010). 
 
Iron is a common transition metal because of its many applications (Huber, 2005). It is used as 
structural backbone of infrastructure as well as other construction applications (Huber, 2005). 
However, iron is not as common in the nanoscale unlike its oxide (Huber, 2005). Iron oxide 
nanoparticles (FeNPs) are stable unlike plain nano-iron, which is pyrophoric making it difficult 
to study (Huber, 2005). But, both are very magnetic and have catalytic properties, which can 
be applied in removing contaminants from bodies of water such as inorganic metals (Huber, 
2005).  
 
FeNPs have a diameter between 1 to 100 nm and can be observed in two forms namely 
magnetite (Fe3O4) and its oxidized form maghemite (Fe2O3), which are stable (Tang and Lo, 
2013). FeNPs are used for magnetic data storage, biosensing, and drug-delivery because of 
their stability and significantly high surface area to volume ratio (Blaney, 2007). FeNPs exhibit 
high magnetic property even at sizes between 2 to 20 nm (Scott et al, 2011). They display super 
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paramagnetism which provides an additional stability (Scott et al, 2011). It is also 
biocompatible and non-toxic (Scott et al, 2011). In Table 1.5, the different synthesis techniques 
that can be applied to produce FeNPs are shown. 
 
Table 1.5: Techniques used to synthesize FeNPs 
Technique Particle Characteristic References 
High-temperature decomposition 
of organic precursors 
Monodisperse, crystalline 
structure, uniform size 
Scott et al, 2011 
Microemulsion or Reverse 
Micelle 
Monodisperse, well-ordered, 
uniform size,   
Blaney, 2007 
Co-precipitation: Ferrous 
hydroxide suspension 
Uniform size  Blaney, 2007 ; 
Mascolo et al, 2013 
Co-precipitation: Ageing 
stoichiometric mixtures 
Uniform size Blaney, 2007 ; 
Mascolo et al, 2013 
Copolymer Templates Structurally stable, uniform size Blaney, 2007 
 
Based on Scott et al (2014), FeNPs could be made by high-temperature decomposition of 
organic precursors (iron carboxylate salts) in the presence of hot organic surfactants (xylenes 
and sodium dodecylbenezensulfonate). This technique could be used in creating FeNPs for 
biomedical application like magnetic resonance imaging, and magnetorelaxometry (Scott et al 
2014).  
 
According to Blaney (2007), showed microemulsion or the reverse micelle technique which 
was a stable isotropic dispersion of 2 immiscible liquids with nanosized domains of one or both 
liquids. This could be done in a water-in-oil system at the presence of an amphiphilic surfactant. 
The presence of the surfactant lowered the surface tension between the 2 immiscible liquids 
(Blaney, 2007). As a result, the water nanodroplets acted as nanoreactors where the 
nanoparticles could be synthesized. Because these nanodroplets acted as carriers of the FeNPs, 
the size of the FeNPs depended on the size of the nanodroplets. As such, if one desired to 
change the size of the FeNPs, one should change the size of the nanodroplets (Blaney, 2007).  
 
FeNPs could also be made by co-precipitation using a ferrous hydroxide suspension which was 
partially oxidized by an oxidizing agent. This was done by reacting iron (III) salt with a base 
21 
 
and a mild oxidant such as nitrate ions. Another process was by co-precipitation which 
consisted of ageing stoichiometric mixtures of iron (II) and iron (III) hydroxides in aqueous 
media at a basic pH between 8 to14. The ratio of iron (III) to iron (II) was 2:1 and the 
environment should be non-oxidizing. The problem with this technique was the susceptibility 
of the particles to oxidation. As a result, it could easily transform the magnetite into maghemite 
(Mascolo et al, 2013). In both co-precipitation techniques, the size of the FeNPs could be 
controlled by adjusting the pH, ionic strength, temperature, nature of the salts used, and the 
concentration ratio of iron (II) to iron (III) (Mascolo et al, 2013). 
 
The last technique is by co-polymer templates. According to the study of Blaney (2007), co-
polymer uses ion exchange resins such as micro-scale styrene beads with divinylbenzene 
crosslinking. These resins were mesoporous (2-50 nm in diameter) containing negatively 
charged sulfonic groups which could exhibit cation exchange. When these templates were 
immersed into the solution of strong positive electrolytes like ferrous iron, the metal loads 
attached to the sulfonic groups on the mesopores. These mesopores then acted as nanoreactors 
(Blaney, 2007).  
 
Once synthesized several modifications can be done to FeNPs depending on the desired 
application. According to Blaney (2007), FeNPs could be coated with a monolayer coat of 
polymer. By doing so, hydrophobic, organic ligand-coated FeNPs were converted into water-
soluble, bio-accessible FeNPs. Because of this coating, the FeNPs were stable at high pH 
values, and temperatures making them untampered when attaching to other molecules. Aside 
from coating it with a polymer, biocompatible coatings could also be used such as 
polysaccharides like dextran and lipid molecules (Blaney, 2007). Innovation in using FeNPs as 
oil spill collectors are also being done. Atta et al (2015), showed that FeNPs could be oxidized 
by air and could aggregate in aqueous solutions because of anisotropic dipolar attraction. To 
prevent aggregation without affecting the magnetic capabilities of the particle, the surface of 
FeNPs were modified by functionalizing the particles with amidoxime (Atta et al, 2015). 
Amidoxime is an amphoteric naturally produced molecule found in rosin gum. The acidic and 
basic sites on amidoxime could prevent aggregation of FeNP particles with each other and 
could attach to hydrophobic molecules (Atta et al, 2015). The coating process is presented on 
Figure 1.8. Because the particles were in a basic medium, the hydroxyl (-OH) groups 
surrounded the FeNPs and bonds to the carboxylic group of amidoxime. Creating a 
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functionalized particle which contained nitrogen (basic sites), carboxylic groups (acidic sites) 
and carbon-hydrogen groups (hydrophobic sites) (Atta et al, 2015). 
 
 
 
In the study of Atta et al (2015), uncoated FeNPs had a removal efficiency that ranged from 10 
% to 45 %. This was far from the removal efficiency of amidoxime coated FeNPs which ranged 
from 70 % to 95 % because the particles were less aggregated with each other exposing more 
binding sites for the hydrophobic oil particles (Atta et al, 2015).  
 
Aside from being an oil spill collector, FeNPs are predominantly used in decontaminating WW 
with heavy metal contamination by applying a magnetic force (Carlos et al, 2013). In the study 
of Carlos et al (2013), the heavy metals adsorbed by FeNPs are Arsenic (V), Lead (II), Mercury 
(II), Copper (II), Cadmium (II) and Chromium (II). All of which have a removal of above 95%. 
This is supported by the study of D’Couto (2008), which analyzed the removal of heavy metals 
like arsenic and lead in wastewater.   
 
Based on the study of Stefusova et al (2012), High Gradient Magnetic Separation was used to 
remove heavy metals from WW. In this process a magnetic field across a column with a 
ferromagnetic matrix was applied (Stefusova et al, 2012). This matrix acted as a magnetic filter 
such that when a magnetic force was applied, the magnetic filling in the column produced a 
large field gradient trapping the FeNPs that were mixed with the contaminated water (Stefusova 
et al, 2012). This process is depicted in Figure 1.9. 
 
Figure 1.8: Synthesis of FeNPs coated with amidoxime (Atta et al, 2015) 
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1.5 Magnetic Activated Carbon  
Though both PAC and FeNPs are being explored and researched on as possible tools in 
decontaminating WW from pharmaceuticals, there are several drawbacks from using these 
process. It is known that activated carbon is excellent and versatile adsorbents. But the lack of 
magnetic property in PAC makes them removable by mechanical filtration or sedimentation 
(Broghi and Fabbri, 2013). The additional removal step of PAC makes it time and cost 
inefficient (Borghi and Fabbri, 2013). On the other hand, solely using FeNPs without any 
coating or functionalization in decontaminating water can be disadvantageous, since it 
naturally aggregate in aqueous solutions limiting its adsorption capacity (Atta et al, 2015).  
Also, the preparation of FeNPs with or without coating requires several steps, specific 
chemicals and procedures that can be costly (Atta et al, 2015). Thus, an efficient way of 
exploiting the capabilities of PAC and FeNPs is by creating a composite adsorbent. 
 
Magnetic Activated Carbon (PACMAG) is a magnetic adsorbent that has the adsorption 
capacity of PAC, and the magnetic property of FeNPs. By creating a composite adsorbent, one 
can increase the particles’ surface area which eventually increases the adsorption capacity for 
contaminants (Kahani et al, 2007). It also makes the particle capable of adsorbing hydrophobic 
contaminants without functionalize or coating it with another chemical. The presence of the 
FeNPs will make it easy to remove from the water by using an external magnetic field (Oliveira 
et al, 2002). According to Safarik et al (2012), magnetic activated carbon (MAC/PACMAG) 
 
Figure 1.9: Schematic diagram of magnetic separation in wastewater 
(Stefusova et al, 2012) 
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have been used by WWTPs to remove various organic and inorganic contaminants ranging 
from humic substances, dyes, oils, mercury, arsenic and phosphates, depicted in Table 1.6.  
 
 
 
A common application of magnetic activated carbon was aurocyanide separation. It was used 
to adsorb and separate gold from alkaline cyanide solutions by mixing a magnetic precursor 
with a carbon source and treating the mixture under controlled conditions. The small particle 
size of PACMAG allowed rapid adsorption of gold, and its magnetic character enabled 
recovery by magnetic separation leading to 99 % efficiency (Tolga, et al, 2014).  
 
Table 1.6: Application of MAC for the separation of 
organic and inorganic compounds (Safarik et al, 2012) 
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Aside from aurocyanide separation, PACMAG are used in WWTP to remove endocrine 
disruptors in the environment. Based on the study of Borghi and Fabbri (2013), the two 
endocrine disruptors, 4-octylphenol and 4-n-nonylphenol, were 95 + 5% until 97 + 1% removed 
from WW using 0.1 - 0.5 g/L of PACMAG. This was done by allowing the contaminated water 
to pass through a magnetic filtration tube filled with stainless steel spheres at the presence of 
an external magnetic field. By doing so, the generated magnetic force was able to capture and 
withhold the adsorbent against the drag force of the surrounding fluid.  
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2 EXPERIMENTAL PART 
 
2.1 Materials and Methods 
2.1.1 Chemicals  
The chemicals used in the synthesis of FeNPs were: iron (III) chloride 6-hydrate (FeCl3.6H2O) 
(Panreac Applichem, Barcelona, Spain), hydrochloric acid (HCl) (VWR International, 
Pennsylvania, USA), sodium sulfate (Na2SO4) (Fisher Scientific International, Inc., Pittsburgh, 
USA), ammonia (NH3) (Panreac Applichem, Bareclona, Spain) and deionized water (ELIX 
Millipore Iberico, S.A.U., Madrid, Spain). Silver nitrate (AgNO3) (Aldrich Chemistry, 
Steinheim, Germany) was used to assess the presence and absence of chloride anion in the 
system after particle washing.  
 
Solutions of sodium chloride (NaCl) (Merck, Darmstadt, Germany) were used to adjust the 
ionic strength when measuring the zeta potential of the particles. Hydrochloric acid (HCl) and 
sodium hydroxide solutions (NaOH) (Merck, Darmstadt, Germany) solutions were used to 
adjust the pH of the solutions.   
 
Powdered activated carbon (PAC) was obtained from Águas do Algarve, S.A. which was used 
in the synthesis of the PACMAG. For the adsorption experiments, DW, and WW (Águas do 
Algarve, S.A.) were mixed with Ibuprofen (IBU) (Jose M. Vaz Pereira, S.A., Lisboa, Portugal), 
Paracetamol (PAR) (Jose M. Vaz Pereira, S.A., Lisboa, Portugal), Amoxicillin (AMOX) (Atral 
Cipan, Castanheira do Ribatejo, Portugal) and Acetylsalicylic Acid (ASA).  The ASA was 
synthesized in the laboratory using salicylic acid (C7H6O3) (Marques & Barroso Lda., Braga, 
Portugal) and acetic anhydride (C4H6O3) (Merck, Darmstadt, Germany) based on the standard 
procedure obtained from literature (Royal Society of Chemistry, 2003). 
 
For the regeneration of magnetic activated carbon (PACMAG), hydrogen peroxide (H2O2) 
(Fisher Scientific International, Inc., Pittsburgh, USA) and hydrochloric acid (HCl) were used.    
 
2.2 Instrumentation  
2.2.1 Zetasizer 
The size and zeta potential (ZP) of the synthesized FeNP were measured using a Zetasizer 
Nano Series Nano-Z590 (Malvern Instruments, Malvern, United Kingdom).  
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2.2.2 Ultraviolet-Visible Spectroscopy (UV-Vis)  
An UV 300 UV-Visible Spectrometer (Spectronic Unicam, Cambridge, UK) was used to 
determine the amount of drugs present in the water. The samples were tested against a blank 
which was DW. The amount of drug present in the sample was determined at the wavelength 
of maximum absorption (λmax) shown in Table 2.1, using the molar absorption coefficient 
experimentally obtained.  
Table 2.1: Pharmaceutical Drugs and its corresponding λmax. 
Pharmaceutical Drugs λmax (nm) 
Ibuprofen (IBU) 221 
Acetyl Salacylic Acid (ASA) 228 
Paracetamol (PAR) 243 
Amoxicillin (AMOX) 228 
 
2.2.3 Other Equipment and Materials 
IKA RCT classic magnetic stirrer (IKA, Staufen, Germany) was used to ensure homogeneity 
of the solutions. All masses were measured using a Mettler AE-240 analytical balance (Mettler 
Toledo, Ohio, U.S.A.). The VWR Ultrasonic Cleaner sonicator (VWR, Pennsylvania, U.S.A.) 
was used to ensure complete dispersion of FeNPs in the solvent. All adsorption experiments 
were done using the Edmund Bűhler GmbH linear shaker (Edmund Bűhler GmbH, Hechingen, 
Germany). Hermle Z300 centrifuge (Hermle Labortechnik GmbH, Wehingen, Germany) was 
used in settling the FeNPs. The amount of total organic carbon (TOC) was determined after 
adsorption using the TOC-5000A Total Organic Carbon Analyzer (Shimadzu, Kyoto, Japan). 
In this research, the TOC content present in the system after adsorption was measured as a 
confirmatory test. In the characterization of the WW, the turbidity and the conductivity of the 
water were analyzed using Hach 2100N Turbidimeter (Hach Company, Colorado, USA) and a 
Crison Conductimeter GLP 32 ( Crison Instruments, SA, Barcelona, Spain) respectively.  
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2.3 General Experimental Flow 
       
 
 
       
 
 
       
 
2.4 Synthesis of adsorbent particles  
2.4.1 Synthesis and Characterization of FeNPs 
FeNPs were synthesized following an adaptation of the method first described by Qu et al 
(1995). In a 150 mL beaker, 16.22 g of FeCl3.6H2O was dissolved in 30 mL of 2M HCl under 
constant stirring for 30 minutes. Then, 30 mL of distilled water have been added. In a separate 
beaker, 2.52 g of Na2SO4 was dissolved in 20 mL of distilled water. The Na2SO4 solution was 
added to the FeCl3 solution under constant stirring for 30 min at 250 rpm. After that and, also 
under constant stirring, the FeCl3-Na2SO4 solution was added to a solution previously made by 
mixing 670 mL of distilled water with 50.8 mL of 25% NH3. The reaction was allowed to take 
place for 30 min at 250 rpm. The particles were magnetically separated and the supernatant 
was decanted.  
 
The FeNPs were pre-washed with distilled water and then with150 mL of 0.1M HCl. To adjust 
the pH to 5-7 and to remove all the ammonium chloride, the particles were washed several 
times with distilled water until the supernatant is negative to the anion chloride test. This test 
consisted in the addition of silver nitrate, being the presence of chloride anions signed by the 
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formation of AgCl2 precipitate. Finally, the particles were washed with ethanol. In each wash, 
the particles were allowed to settle and magnetically separated. The pH of the supernatant was 
measured and then decanted. After the ethanol washing, the particles were air dried for several 
days. The mass of the product was obtained and the percent yield was computed. 
 
A solution of 0.0100g of FeNP in 100 mL of a 0.1M NaCl solution and another with the same 
amount of FeNP in 100mL of a 0.01M NaCl solution were made, the homogeneity of the 
solutions were achieved by sonication for at least 15 minutes. The pH and zeta potential of the 
unsonicated and sonicated FeNPs mixtures have been measured.  The pH of the mixtures were 
adjusted using 3.5 M HCl and 1 M NaOH based on the desired pH. Once the pH was adjusted, 
the pH, ZP, and size of the particles have been measured.  
 
2.4.2 Synthesis and Characterization of PACMAG 
PACMAG were synthesized following an adaptation of the method first described by Kahani 
et al (2007). In a 50 mL beaker, 0.1500 g of FeNPs were added to 15 mL of deionized water 
(DW) and sonicated for 15 minutes, 0.5000 g of PAC was added to the sonicated FeNPs, and 
the mixture was stirred for 15 minutes. The particles of PACMAG were allowed to settle in the 
presence of a magnet for 10 minutes and then decanted. The PACMAG was washed 4 times 
with 10mL of DW, decanting the liquid in the presence of a magnet after each wash.  The 
particles were allowed to air dry for 2 days.  
 
2.5 Characterization of Wastewater (WW) 
The pH, conductivity, turbidity, DOC and TOC of the WW were measured using a pH meter, 
conductimeter, turbidimeter, Total Organic Carbon Analyzer respectively. This was done for 
each batch of the WW to ensure similarity between batches. 
 
2.6 Calibration Curves 
In order to determine the unknown concentration of the treated samples, calibration curves for 
each drug (IBU, PAR, ASA, and AMOX) were created at known concentrations (5 mg/L, 10 
mg/L, 20 mg/L, and 30 mg/L).  The absorbance of the solutions was measured at the λmax (Table 
2.1) of the corresponding drug. The correlation between the known concentration of the sample 
and the measured absorbance was used to develop the calibration curve for each drug.  
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2.7 Adsorption Tests 
2.7.1 Kinetics Measurements 
Four types of experiments, described in Table 2.2, were performed. A specific amount of 
adsorbent was mixed with 100 mL of contaminated water sample. This mixtures were placed 
on a linear shaker at a speed of 150 mpm. Fifteen milliliters, 15 mL, of liquid sample was taken 
at specific times (0 min, 15 min, 40 min, 80 min, 120 min, 160 min, 24 hours) in order to follow 
the adsorption process. The obtained sample was allowed to settle for 5 minutes at the presence 
of the magnet and the particles were magnetically separated.  
Depending on the adsorbent being analyzed, an additional separation technique was done for 
comparison purposes. After magnetic separation, 5 mL of supernatant was centrifuged for 15 
minutes at 4000 rpm.  
Both the pH and absorbance values of the samples were measured. 
 
Table 2.2: Parameters for each case (Adsorbent type, Amount of adsorbent, Type of 
contaminated sample, separation technique performed) 
 
Adsorbent type Amount of 
adsorbent 
Type of contaminated 
water sample 
Separation technique 
Unsonicated 
FeNPs 
0.1 g 30 mg/L (IBU, PAR, ASA) 
drug –DW solution 
Magnetic separation, 
Magnet-centrifuge 
Sonicated 
FeNPs 
10 mL of 1% 
(m/m) FeNPs – 
DW mixture 
30 mg/L (IBU, PAR, ASA) 
drug –DW solution 
Magnetic separation, 
Magnet-centrifuge 
PACMAG 0.1 g 30 mg/L (IBU, PAR, ASA) 
drug –DW solution 
Magnetic separation, 
Magnet-centrifuge 
PACMAG 0.0390 mg 10 mg/L (IBU, AMOX) 
drug –DW solution 
Magnetic separation 
PACMAG 0.0390 mg WW Magnetic separation 
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2.7.2 Isotherms of PACMAG 
Table 2.3: Amount of PACMAG used in accordance to the expected PAC content present in 
the particle 
Amount of PACMAG 
(mg PACMAG/30mL solution) 
Corresponding PAC content 
(mg PAC/L solution) 
3.9 100 
7.8 200 
11.7 300 
15.6 400 
19.5 500 
23.4 600 
27.3 700 
31.2 800 
35.1 900 
39.0 1000 
 
In the isotherm for varying amounts of PACMAG, 30 mL of contaminated water samples 
composed of either a 10 mg/L IBU solution, 10 mg/L AMOX solution, or WW, was mixed 
with varying amounts of PACMAG (100 mg - 800 mg PAC content) (Table 2.3).  
 
While for the second isotherm in which the drug concentration was varied, the optimum amount 
of PACMAG (11.7 mg), that has been obtained from the first isotherm, was dissolved in 30 
mL of the studied drugs, being at five different concentrations (5 mg/L, 15 mg/L, 20 mg/L, 25 
mg/L and 30 mg/L).  
 
In both experiments, samples were taken after 2 hours of adsorption, under constant shaking 
(the linear shaker set to 150 mpm). The obtained sample was allowed to settle for 5 minutes at 
the presence of the magnet and the particles were magnetically separated.  The absorbance of 
the liquid sample was measured at the λmax (Table 2.1) of the corresponding drug in order to 
obtain their concentration.  
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2.7.3 Adsorption of PACMAG in WW Spiked with Drug  
Based on the optimum amounts of PACMAG (11.7 mg) and drug concentration (15 mg/L) of 
IBU or AMOX determined in 2.7.2, the adsorbent was mixed with 30 mL of WW spiked drug 
(IBU or AMOX). Adsorption took place for 2 hours under constant shaking (the linear shaker 
set to 150 mpm). The particles were settled for 5 minutes with the presence of a magnet and 
separated. The absorbance of the liquid sample was measured at the λmax (Table 2.1) of the 
corresponding drug in order to obtain their concentration.  
 
2.8 Regeneration of PACMAG (Preliminary Test) 
PACMAG were regenerated following an adaptation of the method first described by Do et al 
(2011). Thirty milliliters, 30 mL, of 15 mg/L of a solution of AMOX  in wastewater (WW) was 
mixed with different amounts of PACMAG (300 mg- 1000 mg PAC content) (Table 2.3 in 
2.7.2). Adsorption took place for 2 hours under constant shaking (the linear shaker set to 150 
mpm). The particles were settled for 5 minutes with the presence of a magnet and separated. 
The TOC and the absorbance of the liquid sample at 228 nm (Table 2.1) were measured.  
 
The used PACMAG was air dried for 2 days and at 50 oC for 4 hours. Under the hood, the used 
PACMAG was mixed with 100 mL of 0.083 M of H2O2. This mixture was shaken for 8 hours 
on a linear shaker set to 250-275 mpm. The pH was maintained at 2.90-3.10 using a 6 M HCl 
solution during the reaction. After the reaction, the particles were settled for 5 minutes in the 
presence of a magnet and separated. In the presence of a magnet, the regenerated PACMAG 
were washed with 20 ml of DW until pH of the supernatant was neutral. The regenerated 
PACMAG was dried in the oven for 2 days at 50 oC. The dried regenerated PACMAG was 
tested again for adsorption in the AMOX-WW mixture. 
 
2.9 Sedimentation Test of PACMAG  
Three, 3, samples containing 20 mL of a 10 mg/L IBU solution mixed with 7.8 mg of 
PACMAG have been allowed to interact for 2 hours under uniform shaking (the linear shaker 
set to 150 mpm). The first sample was allowed to settle with a magnet for 5 minutes. The 
second sample was allowed to settle for 5 minutes without a magnet, the third sample was 
allowed to settle for 30 minutes without a magnet. The amount of IBU was determined from 
the absorbance at its λma.  
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3 RESULTS AND DISCUSSION 
 
In the present chapter, the obtained results are shown and discussed. Starting in the synthesis 
and characterization of iron nanoparticles used in the adsorbent. The adsorption ability of the 
magnetic activated carbon adsorbent (PACMAG) for IBU, ASA, PAR, and AMOX are 
determined. This adsorbent was also tested in wastewater spiked with IBU and AMOX. Finally, 
preliminary tests on the regeneration and rate of sedimentation of PACMAG were done. 
 
3.1 Synthesis of Adsorbent Material 
3.1.1 Synthesis and Characterization of FeNPs  
The FeNPs are synthesized using the co-precipitation technique following an adaptation of the 
method first described by Qu et al (1999).  Initially, a partial reduction of Fe3+ to Fe2+ by the 
presence of sulfide in acidic medium takes place in order to obtain a 2:1 proportion of iron 
ions. The system is then made basic to precipitate out the FeNPs.  
 
The iron and sulfide will react with each other forming a dark red complex, signifying the 
presence of [FeSO3] + (Equation 3.1) (Betterton, 1993) (Millero et al, 1995).  
 
Fe3+ + SO42-  [FeSO3] +     Equation 3.1 
 
The reaction continues by reducing iron (III) to iron (II), and oxidizing sulfur (IV) (S4+) to 
sulfur (VI) (S6+) (Equation 3.2-3.4) (Karraker, 1963) (Millero et al, 1995). 
 
SO32- + H2O  SO42- + 2H+ + 2e-   Equation 3.2 
2Fe3+ + 2e-  2 Fe2+     Equation 3.3 
2 Fe3+ + SO32- + H2O  2 Fe2+ + SO42- + 2H+ Equation 3.4 
 
Based on the reaction stoichiometry (2 Fe3+: 1 SO32-) and the amount of Fe3+ (one third) that 
can be reduced, the concentration ratio would be [Fe3+] / [SO32-] = 6. However, experimental 
evidences show an optimal concentration ratio of 3 because the solution has not been de-
aerated. In the presence of oxygen and iron ions, as catalysts, the sulfide is oxidized (Equation 
3.5) (Shen et al, 2009). Finally, the addition of ammonia has caused the production of magnetite 
(Equation 3.5-3.6) (Shen et al, 2009). 
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   2SO32- + O2  2SO42-    Equation 3.5 
   2 Fe3+ + Fe2+ + 8OH-  Fe3O4 + 4H2O  Equation 3.6 
 
The FeNPs are obtained in quantitative yield. Comparing to other techniques, the reaction 
produces a high percent yield (Blaney, 2007). The particles were washed with different solvents 
(HCl solution, DW, and ethanol).  
 
The point of zero charge is an important property of nanoparticles. It is the pH at which the 
electrical charge density on the surface of the particle is zero. On the other hand, the isoelectric 
point is the pH at which the colloidal particle remains stationary in an electrical field. The 
isoelectric point of magnetite in water at 25 oC is 6.5-6.7 (Jiang et al., 2010). Often, the 2 terms 
are used indistinctly because their differences are considered to be negligible.  
 
In obtaining the isoelectric point, the zeta potential (ZP) of the particle is needed. Zeta potential 
is the electrokinetic potential in a colloidal dispersion. The zeta potential is the potential 
difference between the dispersion medium and the stationary layer fluid attached to the 
dispersed particle. The zeta potential is caused by the net electrical charge contained within the 
region bounded by the slipping plane, and also depends on the location of that plane. Thus, it 
is widely used for quantification of the magnitude of the charge. However, zeta potential is not 
equal to the Stern potential or electric surface potential in the double layer, because these are 
defined at different locations. Such assumptions of equality should be applied with caution. 
Nevertheless, zeta potential is often the only available path for characterization of double-layer 
properties. The zeta potential is a key indicator of the stability of colloidal dispersion. The 
magnitude of the zeta potential indicates the degree of electrostatic repulsion between adjacent, 
similarly charged particles in a dispersion. For molecules and particles that are small enough, 
a high zeta potential will confer stability, i.e., the solution or dispersion will resist aggregation. 
When the potential is small, attractive forces may exceed this repulsion and the dispersion may 
break and flocculate. So, colloids with high zeta potential (negative or positive) are electrically 
stabilized while colloids with low zeta potentials tend to coagulate or flocculate. 
  
A low ZP magnitude promotes clumping because there is no repulsive force that inhibits the 
FeNPs from aggregating. This is their natural tendency caused by the anisotropic dipolar 
attraction that exists between particles (Atta et al, 2015). 
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In this work, the ZP are measured before and after sonication (Figure 3.2). Figure 3.2 shows 
that the ZP of the particles change because of sonication. The unsonicated particles have a low 
negative ZP compared to the sonicated ones which produced a positive ZP. 
 
 
 
Particles with a low ZP means that they are unstable and colloidal dispersion is low. This was 
observed when aggregates of unsonicated FeNPs settled at the bottom of the beaker. Because 
the particles are not colloidally stable, the sample tested were predominantly composed of DW. 
Because of this, the small amounts of anion such as chlorine caused the slight negative ZP 
(Jiang et al., 2010). Also, the zetasizer was not able to measure the particle size of the 
 
Figure 3.1: Diagram of the 2 layers surrounding the particle 
(Malvern Instruments Limited, 2014) 
 
Figure 3.2: Zeta potential of FeNPs before and after sonication 
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unsonicated FeNPs because of insufficient amount of FeNPs in the liquid sample. On the other 
hand, sonication caused the particles to be less aggregated and be more disperse in the colloidal 
mixture. This resulted in a positive ZP (roughly 25mV) because FeNPs are metallic and are 
positive (Jiang et al., 2010). Based on Table 3.1, FeNPs have an incipient instability means that 
it could be in a colloidal state for a certain amount of time (Jiang et al., 2010).  
 
Table 3.1: The stability of particles based on their zeta potential values (Jiang et al., 2010) 
Zeta Potential (mV) Stability behavior of the colloid 
0 to (+/-) 10 Rapid Coagulation or flocculation 
(+/-) 10 to (+/-) 30 Incipient instability 
(+/-) 30 to (+/-) 40 Moderate stability 
(+/-) 40 to (+/-) 60 Good stability 
More than (+/-) 61 Excellent stability 
 
Size is an important physical property of a particle which is regularly determined by 
manufacturing industries because it can influence the properties of a material (Table 3.2).  
 
Table 3.2: Direct influence of particle size on the property of the material (Malvern 
Instruments Limited, 2014) 
Property affected by particle size Examples 
Reactivity / Dissolution Catalysts, tablets 
Stability in suspension Sediments, paints 
Efficacy of delivery Asthma inhalers 
Texture and feel Food ingredients 
Appearance Powder coatings and inks 
Ability to flow and handling Granules 
Viscosity Nasal spray 
Packing density and porosity Ceramics 
 
In this research, the ZP and the size of the particles were measured in the presence of varying 
pH and ion concentrations (DW, 0.1 M NaCl, and 0.01 M NaCl). Based on the results of the 
previous experiment, the FeNPs were sonicated before measuring the ZP and size. Figure 3.3 
shows that the experimental isoelectric point of the synthesized FeNPs is between pH 8 to 9 
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which coincided with the isoelectric point obtained by Jiang et al, which was at pH 9 (Jiang et 
al., 2010).   
 
 
Based on the graph, the ZP of FeNPs are affected by the ion concentration in the sample, and 
by the pH of the sample. The trend line equations show that the absolute value of the slope 
increases at decreasing ion concentration (0.1 M NaCl until 0 M NaCl = water).  
 
  Trend line of 0.1M NaCl: y= -7.329x + 59.109   Equation 3.7 
  Trend line of 0.01M NaCl: y = -9.7612x + 77.266  Equation 3.8 
  Trend line of water: y = -10.826x + 83.471   Equation 3.9 
 
The absolute value of the slope changes from 7.329 (0.1 M NaCl) to 10.826 (water) (Equations 
3.7, 3.8, 3.9) because the presence of the ions in the mixture cause an unstable distribution of 
surface charge on the particle. As a result of the change in slope, the ZP range (y-axis) of FeNPs 
in the 0.1 M NaCl solution is narrower (ZP = +33- -25) compared to 0.01 M NaCl solution (ZP 
= +38- -40) and water (ZP = +40- -44) because the presence of the ions inhibits colloidal stability 
and promotes particle aggregation.  
 
Depending on the pH of the mixture, sodium and chloride ions can act as a counter ion (Salgin, 
S. et al, 2012). Below the point of 0 value, the particles have a positive surface charge, causing 
chloride anions to act as counter ions. On the other hand, above the point of zero value, the 
sodium cations are the counter ions because the surface charge of the particles is negative 
 
Figure 3.3: Zeta potential of FeNPs in varying ion concentration and pH 
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(Salgin, S. et al, 2012). The counter ions act as a screen, weakening the particles’ repulsive 
forces between each other and promoting aggregation (Salgin, S. et al, 2012). As a result, the 
ZP is lower and the particles sizes are bigger (AZoNano, 2005). In general, the higher the ion 
concentration, the more counter ions present which leads to a stronger screening effect (Figure 
3.4).    
 
 
The pH of the sample affects the behavior of FeNPs as well. In basic pH, the high hydroxide 
(OH-) concentration causes the particles to acquire more negative charge, making the zeta 
potential to be more negative. While in acidic solutions, the addition of HCl causes an increase 
in hydronium (H3O+) ions leading to the build-up of positive charges (Figure 3.3) (AZoNano, 
2005). In both cases, the increase in charges causes an increase in repulsive forces between 
particles leading to a higher ZP magnitude. While, at neutral pH the zeta potential is positive 
because even though there are no added hydronium ions, by the presence of the iron in the 
particles makes the particles’ surface to be positive.  
 
The effects on the ZP magnitude is reflected on the stability of the colloidal system and on the 
particle size. In all three solvent types, the pH values near the point of 0 charge has the biggest 
particle size because this is when the repulsive force between particles are the weakest (Figure 
 
Figure 3.4: Flocculation scheme in solvent systems with 
and without salts (Stoll, 2013) 
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3.5).  Unlike in basic and acidic cases wherein the repulsive force between particles are higher. 
Also, the absence of counter ions make the particles less aggregated minimizing particle size.  
 
 
3.1.2 Synthesis and Characterization of PACMAG 
Though studies show that FeNPs can be used as adsorbent, its adsorption capacity is minimal 
due to its natural tendency to aggregate in aqueous medium. On the other hand, PAC is difficult 
to remove in the water system. Often an additional filtration step is needed which can be time 
consuming. The new adsorbent material, PACMAG, combines the adsorption capacity of PAC 
and the magnetic property of FeNPs to address each other’s drawbacks. PACMAG were 
synthesized following an adaptation of the method first described by Kahani et al (2007). 
Because PAC is highly porous, a possible way of embedding FeNPs is by adsorption which 
produces quantitative yield (103 ± 5 %). Though some of the adsorption sites of PAC are 
already occupied by the FeNPs, it can still adsorb a good amount of contaminants. Also, it can 
be regenerated for multiple usage which is cost efficient. The average percent yield is above 
100 % because the particles are not completely dry. Similar with the synthesis of FeNPs, the 
particles can trap liquid such as DW, which was the liquid used to wash the particles. The 
presence of DW in PACMAG has no effect on the adsorption experiments because water was 
used as sample. Its effect on the mass of PACMAG used per experiment is minimal as well 
because the mass contribution of water versus the mass contribution of PAC and FeNPs is just 
7% per mole of PACMAG.  
 
 
Figure 3.5: Particle size of FeNPs in varying solvent systems and pH 
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3.2 Characterization of Wastewater (WW) 
Because the particles were also tested in actual WW, water from the Estação de Tratamento de 
Águas Residuais of Águas do Algarve, SA was obtained and characterized. A problem with 
using WW in adsorption experiments is that its components are unknown, and the amount of 
contaminants vary depending on when the wastewater has been collected. Thus, it is important 
to monitor the pH, conductivity, turbidity, dissolve organic carbon (DOC), and total organic 
carbon (TOC) of the batches of WW used in order to minimize variations in the results (Table 
3.3).  
Table 3.3: Properties of WW 
Property Average 
pH 7.71 ± 0.04 
Conductivity ((μs/cm) 1293 ± 16 
Turbidity 1.70 ± 0.03 
DOC (ppm) Batch  1 7.89 ± 0.06 
Batch 2 7.34 ± 0.13 
Batch 3 8.63 ± 0.39 
TOC (PP) Batch 1 9.73 ± 0.14 
Batch 2 8.79 ± 0.05 
Batch 3 9.05 ± 0.40 
 
The isotherms using WW as sample were measured, for a 24 hour time period,  as well in order 
to confirm if PACMAG can adsorb contaminants that interfere with the signal measured by 
UV-VIS at the λmax of IBU (221 nm) and AMOX (228 nm). Considering the presence of 
unknown contaminants in WW, competition between those contaminants and the monitored 
drugs can occur. By determining the isotherms of contaminants dissolved in WW adsorption 
on PACMAG (300 mg/L PAC content), the minimum time for maximum contaminant removal 
can be determined. Figure 3.12 shows the minimal decrease in the absorbance values for both 
λmax is after 120 minutes. So 120 min (2 h) is the minimum amount of adsorption time needed 
by PACMAG in WW (Figure 3.5). This minimum decrease in adsorption after 120 minutes is 
because the adsorption capacity of PACMAG is slowly being reached. There is a decreasing 
amount of available adsorption sites because PACMAG follows the Langmuir isotherm, 
similar with PAC (Tan and Hameed, 2010). Langmuir isotherm assumes a monomolecular 
isotherm behavior which contains fixed individual sites that equally adsorbs a molecule 
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forming a monolayer with the thickness of the adsorbed molecule (Tan and Hameed, 2010). 
Thus, once an adsorption site is occupied by a contaminant, another contaminant cannot occupy 
the same space. This is why after 300 mg/L of PAC content, the graph flattens out (Figure 3.6).  
 
 
 
The isotherm of WW in the presence of varying amounts of PACMAG (100 mg/L PAC - 600 
mg/L PAC content) is performed to determine the optimum amount of PACMAG that can 
adsorb a maximum amount of contaminant. Figure 3.7 shows that beyond 300 mg/L of PAC 
content there is no drastic change in the absorbance of WW at both wavelengths. This PAC 
content amount is used as the minimum amount of PACMAG needed to remove IBU or AMOX 
in WW (Figure 3.7). The minimal decrease of absorbance after 300 mg/L PAC content is 
because of the insufficient amount of contaminants left in the water that can be adsorbed. As a 
result, the percent removal of IBU and AMOX had a minimal increase after 300 mg/L PAC 
presented in Figure 3.8. 
 
 
Figure 3.6: Absorbance of wastewater water in the presence of PACMAG at 221 nm for IBU 
and at 228 nm for AMOX in a 24 hour adsorption period 
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Figure 3.7: Isotherm of the absorbance of wastewater water in the presence of varying amounts 
of PAC content in PACMAG at 221 nm for IBU and at 228 nm for AMOX  
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Figure 3.8: Absorbance of wastewater water in the presence of varying amounts of PAC content 
in PACMAG at 221 nm for IBU and at 228 nm for AMOX (ERROR) 
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3.3 Calibration Curves 
Calibration curves were established for each type of aqueous drug solution using the UV-Vis 
absorption at their respective λmax. The calibration curves for each type of drug are shown in 
Figure 3.9. All calibration curves are considered to be an accurate form of detection for their 
respective drug with a concentration of 30 mg/L and below. These were used to calculate for 
the experimental drug concentration after adsorption based on their absorbance values. 
 
 
 
3.4 Adsorption Test of FeNP  
Adsorption is one of the common techniques applied in WWTPs used in removing particulates 
and chemical contaminants. Adsorption involves the binding of particles on a surface which 
involves intermolecular forces of attraction. But not all types of material can be used as 
adsorbent. The common industrial adsorbent are activated carbon, silica gel, and alumina 
because these materials have a big surface area per unit weight. In this research, adsorption is 
often used to assess the efficiency of FeNPs and PACMAG as adsorbents in removing IBU, 
(A)  (C)  
(B)  (D)  
Figure 3.9: Calibration curves of (A) IBU, (B) PAR, (C) ASA, and (D) AMOX 
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PAR, ASA, and AMOX in water. 4 different experimental set-ups were performed and studied 
which are depicted in Table 3.4. 
 
Table 3.4: Experimental set-ups for drug adsorption of either FeNPs or PACMAG 
Adsorbent type Amount of 
adsorbent 
Type of contaminated 
water sample 
Separation technique 
Unsonicated 
FeNPs 
0.1 g 30 mg/L (IBU, PAR, ASA) 
drug –DW solution 
Magnetic separation, 
Magnet-centrifuge 
Sonicated 
FeNPs 
10 mL of 1% 
(m/m) FeNPs – 
DW mixture 
30 mg/L (IBU, PAR, ASA) 
drug –DW solution 
Magnetic separation, 
Magnet-centrifuge 
PACMAG 0.1 g 30 mg/L (IBU, PAR, ASA) 
drug –DW solution 
Magnetic separation, 
Magnet-centrifuge 
PACMAG 0.0390 mg 10 mg/L (IBU, AMOX) 
drug –DW solution 
Magnetic separation 
PACMAG 0.0390 mg WW Magnetic separation 
 
3.4.1 Kinetics Measurements of IBU, PAR, ASA in FeNPs 
The adsorption capacity of FeNP is tested by changing its form through sonication, and by 
varying the separation technique of the adsorbent before UV-Vis analysis. There is a minimal 
decrease in the absorbance values of the samples after adsorption with unsonicated FeNPs. 
Though samples that are separated by a combination of magnet and centrifuge are lower in 
absorbance values than the magnetically separated samples, the amount of drugs removed of 
both techniques are very small (Figure 3.10, Figure 3.11). 
45 
 
 
 
 
The same trend is observed in the sonicated FeNPs. The samples that were separated with a 
combination of magnet and centrifuge had lower absorbance measurements, resulting to lower 
drug concentration (Figure 3.12). Comparing the two treatments on FeNPs, sonication 
increases the capacity of the FeNPs to adsorb contaminants because the particles are smaller 
compared to the unsonicated FeNPs. The sonicated FeNPs are more dispersed in a colloidal 
system and not aggregated leading to a bigger surface area and more available adsorption sites.  
 
Figure 3.10: Absorbance measurements of IBU samples in the kinetic experiment of 
unsonicated FeNPs 
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Figure 3.11: Concentration of IBU samples in the kinetic experiment of unsonicated FeNPs  
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Because sonicated FeNPs and separation using a combination of magnet and centrifuge 
produced better absorbance results for IBU, similar parameters were applied in the adsorption 
experiment of ASA and PAR. Because IBU, PAR and ASA have similar molecular structures, 
it is expected that the adsorption behavior of ASA and PAR will be similar with IBU. Figure 
3.13 shows the absorbance values of the three drugs after 24 hours of adsorption on PACMAG 
(Figure 3.13). Calculating for the amount of drugs adsorbed after 24 hours, it can be said that 
sonicated FeNPs adsorbed PAR the least, followed by ASA. The drug that is adsorbed the most 
is IBU which coincides with their respective percent removals (Figure 3.14).  
 
Though all three are partially adsorbed by FeNPs, the adsorption difference are minimal 
because of the solubility of IBU, PAR and ASA in water. All three drugs have polar functional 
groups, carboxyl group for IBU and ASA, and a hydroxyl group for PAR, which can interact 
with water. Also, all three drugs are weak acids causing a decrease in pH, a positive ZP, and a 
higher colloidal stability. But, because of the presence of the aromatic ring in their structure, 
these drugs become partially insoluble in water (Shen et al, 2009). The partial insolubility of 
the HPCs limits the full surface contact between the drugs and FeNPs (Shen et al, 2009). As a 
result, there is insufficient adsorption, resulting to low percent removal. The maximum percent 
removal are 27.21 ± 0.14% (IBU), 10.70 ± 0.02% (PAR), and 16.97 ± 0.05% (ASA) (Figure 
3.13).  
 
Figure 3.12: Concentration of IBU samples in the kinetic experiment of sonicated FeNPs  
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3.4.2 Kinetics Measurements of IBU, PAR, ASA in PACMAG 
The adsorption capacity of PACMAG with IBU, PAR, and ASA is determined in order to 
compare its efficiency with FeNPs. Figure 3.14 shows the absorbance, sample concentration, 
and percent removal of all 3 drugs with PACMAG. After 120 min, the adsorption capacity of 
PACMAG is slowly reaching its limit. The change in the absorbance measurements as time 
elapses is decreasing because the adsorption sites are slowly being occupied by the 
contaminants. Among the 3 drugs, PAR is adsorbed the most having a percent removal of 99.47 
± 0.02%, while ASA is adsorbed the least having a percent removal of 93.95 ± 0.02% (Figure 
3.15). IBU has a percent removal of 95.93 ±0.01%. As a representative of the analgesic group 
 
Figure 3.13: Absorbance measurements of the drug samples in the kinetic experiment of 
sonicated FeNPs using magnetic separation and centrifuge 
Drug 0 min 40 min 80 min 120 min 160 min 24 hours
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Figure 3.14: Percent removal of the drug samples in the kinetic experiment of sonicated 
FeNPs using magnetic separation and centrifuge 
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which is prevalently detected in most bodies of water and is vastly produced, IBU was further 
tested for its adsorption in PACMAG. This was then compared with the behavior of AMOX, a 
common antibiotic 
 
 
A)  
 
B)  
 
C)  
Figure 3.15: Absorbance (A) and concentration (B) of the samples at varying times of 
adsorption using PACMAG as adsorbent and its corresponding percent removal (C) 
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To mimic environmental drug concentrations without going lower than the UV-Vis detection 
limit, the concentration of IBU was lowered to 10 mg/L in the adsorption tests. Figure 3.16 
shows that IBU behaves similarly with the previous kinetic experiment which involved a higher 
IBU concentration. The changes in absorbance measurements beyond 120 minutes of 
adsorption are minimal which signified that the adsorption capacity of PACMAG is slowly 
being reached (Figure 3.16). 
 
 
 
Based on the gathered data, PACMAG is able to decrease the IBU concentration dramatically 
after 2 hours of adsorption, from an initial concentration of 10 mg/L to roughly 0.30 mg/L, 
resulting into a 92.99 ± 0.01 % removal (Figure 3.17 A and B). The high percent removal 
coincides with the percent removal of 30 mg/L IBU in PACMAG which is 95.93 ± 0.01%. It 
can be seen as well that adsorption takes place as soon as the PACMAG is placed in the system, 
resulting into an immediate decrease from the initial concentration. Though previous studies 
showed that complete removal of IBU was possible with magnetic activated carbon 
(Stackelberg et al, 2004), this is not applicable with PACMAG because of a decrease in 
adsorption sites. Some of the pores of PACMAG are already occupied by FeNPs and are not 
available for adsorption.  
 
Figure 3.16: Absorbance of IBU at varying times of PACMAG exposure 
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Aside from IBU and other analgesics, another common drug present in most bodies of water 
are antibiotics such as sulfamethoxazole, trimethoprim, ciprofloxacin, erythromycin and many 
more (Baghapour et al, 2014). For this experiment, the antibiotic used was amoxicillin. The 
kinetics of AMOX in DW was conducted in order to determine the minimum amount of time 
at which PACMAG could adsorb a significant amount of AMOX (Figure 3.18). To make it 
comparable with the kinetics of IBU, the same amount of drug and of PACMAG in the previous 
experiments were used. 
A)  
 
B)  
Figure 3.17: Concentration (A) of IBU at varying times of PACMAG exposure, Percent removal (B) of IBU 
at varying times of PACMAG exposure 
10.323
7.223
3.794
2.275
1.066
0.297 0.271 0.237
0.000
2.000
4.000
6.000
8.000
10.000
12.000
Ibuprofen 0 15 40 80 120 160 24
C
o
n
ce
n
tr
at
io
n
 (
m
g/
L)
Time (min except 24 hours)
0.00
28.58
60.19
74.20
85.35
92.44 92.68 92.99
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
Ibuprofen 0 15 40 80 120 160 24
%
 R
em
o
va
l
Time (min except 24 hours)
51 
 
 
 
As in the case of IBU, PACMAG was able to adsorb AMOX effectively, decreasing the AMOX 
concentration from 10.4 ± 0.1 mg/L to 1.7 ± 0.3 mg/L in 2 hours (Figure 3.19 A). Also, there 
is a sudden decrease in AMOX concentration (1.673 mg/L) as soon as PACMAG is placed in 
the system. It is observed that for times of exposure beyond 120 minutes, the variation of the 
percent removal values was negligible (Figure 19 B). Similarly with the previous experiments, 
the adsorption capacity of PACMAG is slowly being reached because the sites of adsorption 
are limited. Although, the percent removal of IBU is greater than of AMOX, the general 
removal efficiency of PACMAG to both drugs are high. 
 
Figure 3.18: Absorbance of AMOX at varying times of PACMAG exposure 
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3.5 Isotherms of PACMAG 
The isotherms for IBU and AMOX solutions were created by varying the amount of PACMAG 
and by varying the concentration of the drugs. The particles are exposed with the drugs for 120 
minutes which is based on the previous experiments.  
 
3.5.1 Varying Amounts of PACMAG 
By varying the amount PACMAG, the PAC content also varies. Through this isotherm, one 
can determine the minimum amount of adsorbent that is needed to remove an acceptable yet 
sufficient amount of drug from a 10 mg/L starting concentration. By doing so, the material 
usage is maximized, leading to a more cost effective experiment.  
A)   
 
B)  
Figure 3.19: Concentration (A) of AMOX at varying times of PACMAG exposure, Percent removal 
(B) of AMOX at varying times of PACMAG exposure 
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Figure 3.20 shows that the increase in PACMAG increases the amount of IBU or AMOX 
removed because the increase in PAC content increases the adsorption sites that are available 
for adsorption. Similar with other figures, the graph flattens out at a specific quantity. In both 
graphs, beyond 300 mg/L, the difference in the absorbance measurements decreases. This is 
not caused by the lack of adsorption sites or the limited adsorption capacity of PACMAG. 
Rather, the amount of drugs that can be adsorbed by the adsorbent is limited. Because the 
concentration of IBU or AMOX in all set-ups are equal, the amount of PACMAG in a set-up 
outweighs the amount of drug that could be adsorbed. This is why even though the amount of 
PAC content is increased by 400 mg/L, from 300 to 700 mg/L, there is only a minimal increase, 
4.39 ± 0.23 % (IBU) and 10.49 ± 0.18 % (AMOX), in the percent removal of the contaminant 
(A)  
 
(B)  
Figure 3.20: Isotherm of the absorbance of (A) IBU and (B) AMOX at varying 
amounts of PAC content in PACMAG 
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(Figure 3.21 A and B). Taking into consideration the minimal amount of drugs removed versus 
the big amount of adsorbent used, 300 mg/L PAC content in PACMAG is the optimum amount 
of adsorbent that can be used for adsorption. It will be uneconomical to use more materials for 
a minimal difference. 
 
 
 
3.5.2 Varying Concentration of Drug 
Using 300 mg/L PAC content, the maximum amount of IBU or AMOX that it can adsorb is 
determined. This is done by exposing varying concentrations of IBU or AMOX solutions to a 
(A)  
 
(B)  
Figure 3.21: Percent removal of (A) IBU and (B) AMOX at varying amounts of PAC content 
in PACMAG 
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consistent amount of PACMAG. Determining the optimum amount of drugs is important 
because the adsorption capacity of the adsorbent is maximized. The initial drug concentrations 
ranges from 5 mg/L - 30 mg/L. Figure 3.22 A and B shows that the absorbance measurements 
of the IBU and AMOX samples after adsorption are low. The low absorbance trend is evident 
until 15 mg/L drug concentration. 
 
 
The absorbance measurements start to drastically increase after 15 mg/L IBU because the 
adsorption capacity of PACMAG is slowly being reached. Drug saturation occurs when the 
amount of PACMAG is insufficient to adsorb the drug present in solution. As a result, the 
(A)  
 
(B)  
Figure 3.22: Isotherm of the absorbance of (A) IBU and (B) AMOX at varying initial IBU 
concentration  
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natural tendency is to leave some drugs unadsorbed causing an increase in absorbance value 
and a decrease in percent removal (Figure 3.23 A and B). It is evident that with only a 5 mg/L 
increase in drug concentration (15 mg/L to 20 mg/L), the percent removal drastically decreased 
by 6.19 ± 0.08 % (IBU) and 16.11 ± 0.05 % (AMOX). Unlike between 5 mg/L and 15 mg/L 
wherein the total difference is 3.60 ± 0.22 % (IBU) and 13.33 ± 0.16% (AMOX). Because of 
this, the optimum initial drug concentration that PACMAG (300 mg PAC content) can adsorb 
is 15 mg/L. Any drug concentration below it can be removed efficiently by PACMAG. While 
any concentration above it can cause a drastic decrease in percent removal.  
 
 
 
(A)  
 
(B)  
Figure 3.23: Percent removal of (A) IBU and (B) AMOX at varying initial IBU concentration  
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The slight percent removal decrease in the 25 mg/L AMOX concentration (Figure 3.23 B) is 
due to the presence of unremoved PACMAG in the sample which blocked the UV-Vis light 
beam causing it to be undetected by the machine.  
 
3.6 Adsorption of PACMAG in WW Spiked with Drug  
The parameters from the kinetics and the two isotherm experiments of IBU and AMOX, 
namely 120 min of adsorption exposure, 300 mg/L PAC content in PACMAG, and 15 mg/L 
drug concentration, are used in the actual adsorption of WW spiked with either IBU or AMOX 
(IBU- WW, AMOX-WW). Unlike in the previous experiments where the drugs are mixed with 
DW, WW is more difficult to measure the amount of drug that PACMAG can adsorb. This is 
because the amount of contaminants within WW are unknown. Thus, the probability of 
competition between contaminants can occur and affect the adsorption capability of PACMAG. 
To control variations in the contaminants only a single batch of WW is used in the whole 
experiment.  
 
Figure 3.24 A and B shows the amount of drugs in the solution after being exposed with 
PACMAG for 2 hours. There is a 7.43 ± 0.15 mg/L (IBU) and 3.98 ± 0.01 mg/L (AMOX) 
decrease in the amount, resulting to a 49.52 ± 0.15% (IBU) and 26.54 ± 0.01% (AMOX) 
removal. The decrease in percent removal from 92.22 ± 0.08 % (IBU) and 79.90 ± 0.05% 
(AMOX) in DW is due to the presence of competing unknown contaminants in WW. It has 
been observed that some unknown contaminants in WW can adsorb at the same λmax of IBU 
and AMOX. Because of this, it cannot be determined if all of the 49.52 ± 0.15% (IBU) and 
26.54 ± 0.01% (AMOX) of contaminants removed are purely IBU and AMOX.  
 
Comparing the adsorption of IBU and AMOX in both DW and WW water, it is evident that 
PACMAG has a higher percent removal in IBU than in AMOX. This is because certain 
penicillin-derived compounds such as AMOX are unstable in aqueous solution and behaves 
differently at varying pH conditions. Depending on the pH, AMOX exists in its zwitterionic 
form due to the dissociation of the carboxylic group and the protonation of the amine group in 
its molecular structure (Moradi, 2015). Because the surface of PAC which is the main material 
of PACMAG is negatively charged, there is a repulsive interaction that exists between the 
carboxylic group of AMOX and the surface of PACMAG (Mansouri et al, 2015). This limits 
the amount of AMOX that can be adsorbed.  Unlike in IBU, which is a weaker electrolyte than 
AMOX, the neutral and the protonated form of IBU are more dominant in solution than its 
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negative form. Because of this, it is easier for IBU to attach on the surface of PACMAG 
(Mansouri et al, 2015). 
 
 
 
3.7 Regeneration of PACMAG (Preliminary Test) 
Because of the low removal of AMOX in WW, AMOX is chosen to be further optimized. 
AMOX is also used in the regeneration experiment of PACMAG to see if the PACMAG can 
be recycled. PACMAG has been regenerated by following an adaptation of the method first 
(A)  
 
(B)  
Figure 3.24: Amount of (A) IBU and (B) AMOX in the drug- WW mixture before and after 
adsorption  
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described by Do et al (2011). The regeneration experiment makes use of the Fenton reaction 
wherein hydrogen peroxide (H2O2) is used to remove the adsorbed contaminants on the 
adsorbent with the assistance of a metal catalysts (FeNPs) (Do et al, 2011). The metal catalyst 
will generate a highly reactive hydroxyl radical (.OH) from the hydrogen peroxide (equation 
3.10 and 3.11) (Barbusinski, 2009). 
   Fe2+ + H2O2  Fe3+ + .OH + OH-   Equation 3.10 
   Fe3+ + H2O2  Fe2+ + .OOH + H+   Equation 3.11 
 
The hydroxyl radical will react with the contaminants on the PACMAG. The reaction can either 
be through addition, hydrogen abstraction, electron transfer or radical interaction (Table 3.5). 
 
Table 3.5: Four kinds of reactions by hydroxyl radical (.OH) with pollutants  
(Muranaka et al, 2010) 
Reaction Type Example 
Addition .OH + C6H6  (OH)C6H6 
Hydrogen Abstraction OH + CH3OH  CH2OH + H2O 
Electron Transfer .OH + [Fe(CN)6]4-  [Fe(CN)6]3- + OH- 
Radical Interaction .OH + .OH  H2O2 
 
Figure 3.25 compares the absorbance values of the AMOX- WW set-ups that are exposed to 
the new PACMAG and regenerated PACMAG adsorbent. For the 1000 mg/L PAC content, 
there is a 0.457 (new PACMAG) and a 0.311 (regenerated PACMAG) decrease in absorbance. 
 
 
 
Figure 3.25: Comparison of absorbance of new PACMAG and regenerated PACMAG in the 
adsorption of AMOX in AMOX- wastewater  
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Figure 3.26 shows that by increasing the amount of PACMAG to 1000 mg/L PAC content, the 
percent removal of AMOX can be increased to 76.720 ± 0.001 % from a dismal 44.15 ± 0.01%. 
At the same time, the particles can be regenerated because the percent removal of the 
regenerated PACMAG is satisfactory (53.840 ± 0.004%) (Figure 3.26).  
 
Aside from the absorbance and percent removal measurements, the total organic carbon (TOC) 
of the two adsorbents was measured as a confirmatory test. Figure 3.27 shows that the TOC 
values of the initial AMOX- WW mixtures are consistent, making them comparable. It can be 
seen that as the amount of PACMAG (new and regenerated) increases, the TOC concentration 
decreases because more adsorbent are present to adsorb the organic matter. Also, the higher 
TOC values of regenerated PACMAG coincides with the fact that it adsorbed a lesser amount 
of contaminant than the new PACMAG. The regenerated PACMAG have a lower adsorption 
capacity because its pores are previously occupied.  
 
 
Figure 3.26: Comparison of the percent removal of PACMAG and regenerated PACMAG in 
the adsorption of AMOX in wastewater -AMOX  
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Figure 3.27: Comparison of the total organic carbon (TOC) concentration (ppm) of 
samples that were exposed to new PACMAG and regenerated PACMAG 
 
15.70
11.80
6.45 6.29
5.75
15.11
12.50
10.90
9.69
8.79
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
Etar-Amox 300 600 800 1000
TO
C
New PACMAG
Regenerated
PACMAG
61 
 
3.8 Sedimentation Test of PACMAG  
The sedimentation test was done to compare the rate of sedimentation of PACMAG in the 
presence and absence of a magnetic field. Because some of the pores of PACMAG are occupied 
by FeNPs, the adsorption capacity of PACMAG is lower than PAC. As such, it is necessary to 
determine if PACMAG can outperform the commonly used PAC in terms of the rate of 
sedimentation and time needed for separation. Because PAC takes a longer time to settle down, 
it cannot be separated from water immediately. Thus, WW treatment facilities tend to use an 
additional filtration step to remove the PAC. This is an added cost in terms of materials, effort, 
and time (Borghi and Fabbri, 2013). 
 
The sedimentation experiment composed of 3 different set-ups: 5 min with the presence of a 
magnetic field, 5 minutes without the presence of a magnet, and 30 minutes without the 
presence of a magnet (Figure 3.28). Based on the graph, the efficiency of PACMAG in 
adsorbing IBU is very high because it almost removed most of the IBU in the solution. 
 
 
 
But among the three types of sedimentation set-ups, the set-up of 5 minute sedimentation in 
the presence of a magnet has the most favorable result, resulting to a negligible final IBU 
concentration and a 92.38 ± 0.16% removal (Figure 3.29 A and B). This is in accordance with 
the results obtained by Borghi and Fabbri (2013), where in at the presence of a magnetic field, 
the amount of contaminants in the samples were lower than those separated without a magnetic 
field.  
 
Figure 3.28: Absorbance of IBU in varying sedimentation set-ups 
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Figure 3.30 shows that at 5 minutes with a magnet, most of the PACMAG are already at the 
bottom of the beaker creating a non-turbid sample. This is supported by the study of Borghi 
and Fabbri (2013), wherein among the 3 separation techniques, magnetic separation is the least 
turbid because the adsorbent settled very fast (Figure 3.31). 
A)   
 
B)  
Figure 3.29: Concentration (A) of IBU in varying sedimentation set-ups, Percent removal (B) of 
IBU in varying sedimentation set-ups 
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Figure 3.30: Trial 1-3 of the sedimentation of PACMAG with the presence of a magnet 
after 5 min 
 
 
Figure 3.31: Turbidity of the different sedimentation set-ups as time passes (Borghi and 
Fabbri, 2013) 
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4 CONCLUSION & RECOMMENDATION 
This work was done with an aim of developing a composite magnetic activated carbon 
adsorbent (PACMAG) which could remove model drugs (IBU, PAR, ASA, and AMOX) 
from deionized water and wastewater samples. Pharmaceutical drugs are an emerging 
concern because of their presence in the environment and the inadequacy of WWTPs in 
removing them. Based on the research done, PACMAG was a more efficient adsorbent than 
PAC and FeNPs because it had a high adsorption capacity, it could be magnetically separated 
and regenerated. All of which could minimize the overall water treatment cost. 
 
Based on the objectives presented, the main conclusions of this research work are: 
 The synthesis techniques performed in creating the FeNPs and PACMAG were very 
efficient producing quantitative yields. The synthesized adsorbents had the desired 
properties: positive ZP and size measurement for FeNPs, and adsorption capacity and 
magnetic property for PACMAG.  
 IBU, PAR or ASA were adsorbed in low amounts by FeNPs, exhibiting a removal of 
27.21 ± 0.14 %, 10.70 ± 0.02 % and 16.97 ± 0.05 % respectively. Having an aromatic 
ring in the molecular structure of the 3 drugs, they are partially insoluble in water. 
This limited the surface interaction with the adsorbent. 
 In DW, PACMAG was able to adsorb the drugs efficiently producing 92.22 ± 0.08 % 
(IBU), 97.54 ± 0.01 % (PAR), 90.21 ± 0.01 % (ASA), and 79.90 ± 0.05 % (AMOX) 
removal.  
 In WW, PACMAG was able to adsorb IBU and AMOX. But, inhibition by unknown 
contaminants present in WW was evident. This could have caused the removal to 
decrease to 49.52 ± 0.15 % and 26.54 ± 0.01 % for IBU and AMOX respectively. 
This could be optimized by increasing the PAC content to 1000 mg/L, resulting to a 
76.720 ± 0.001% removal for AMOX. 
 PACMAG with a 1000 mg/L PAC content could be regenerated. The regenerated 
PACMAG was able to remove 53.84 ± 0.004 % of contaminants. The decrease in 
removal between the regenerated and new PACMAG was caused by the incomplete 
oxidation of the contaminants that were previously attached on the surface of the 
adsorbent.  
 PACMAG only required 5 minutes to settle when exposed to a magnetic field 
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Knowing the potential of PACMAG as an efficient adsorbent for common drugs like IBU, 
AMOX, PAR and ASA, this experiment can be further improved on by doing the following, 
 Optimizing the regeneration experiments,  
 Exploring the adsorption of other HPCs like drug metabolites, hormones and 
endocrine disruptors 
 Using other metallic nanoparticles as composite material 
 Using other forms of carbon like graphene 
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